tazobactam has been researched along with cephalosporin c in 433 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (cephalosporin c) | Trials (cephalosporin c) | Recent Studies (post-2010) (cephalosporin c) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 20,476 | 2,093 | 4,152 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.23) | 18.7374 |
| 1990's | 26 (6.00) | 18.2507 |
| 2000's | 32 (7.39) | 29.6817 |
| 2010's | 203 (46.88) | 24.3611 |
| 2020's | 171 (39.49) | 2.80 |
| Authors | Studies |
|---|---|
| Girlich, D; Leclercq, R; Naas, T; Nordmann, P | 1 |
| Aspinall, S; Corkill, JE; Hart, CA; McLennan, AG | 1 |
| Bauernfeind, A; Eberlein, E; Jungwirth, R; Schweighart, S | 1 |
| Dornbusch, K; Göransson, E; Mörtsell, E | 1 |
| Acar, JF; Billot-Klein, D; Carlet, J; Goldstein, FW; Gutmann, L; Kitzis, MD; Tran Van Nhieu, G; Williamson, R | 1 |
| Cony Makhoul, P; Darmaillac, V; Fourche, J; Maugein, J; Perrier, F | 1 |
| Harris, EB; Hastings, RC; Prabhakaran, K; Randhawa, B | 1 |
| Gorbach, SL | 1 |
| Denny, BJ; Lambert, PA; Toomer, CA | 1 |
| Bush, K; Lee, VJ; Macalintal, C; Rasmussen, BA; Yang, Y | 1 |
| Alonso, JM; Fournier, JL; Jacolot, AC; Petitjean, OJ; Ramisse, F; Scavizzi, MR; Szatanik, M | 1 |
| Alós, JI; Balas, D; Cogollos, R; Gomez-Graces, JL; Tajada, P | 1 |
| Livermore, DM; Yuan, M | 1 |
| Knapp, CC; Ludwig, MD; Pohlman, JK; Washington, JA | 1 |
| Blumer, JL; Bonafede, ME | 1 |
| Eliopoulos, GM; Moellering, RC; Thauvin-Eliopoulos, C; Tripodi, MF | 1 |
| Hanaki, H; Nagayama, A; Nomura, S | 1 |
| Constantoulaki, S; Paniara, O; Platsouka, E; Zissis, NP | 1 |
| Barthélémy, M; Caniça, MM; Caroff, N; Dupret, JM; Krishnamoorthy, R; Labia, R; Paul, G | 1 |
| Amicosante, G; Cornaglia, G; Franceschini, N; Mazzariol, A; Perilli, M; Segatore, B; Setacci, D | 1 |
| Böhme, A; Hoelzer, D; Shah, PM; Stille, W | 1 |
| Andremont, A; Guy, H; Marie, JP; Pico, JL; Richet, H; Vekhoff, A | 1 |
| Baudard, M; Bouvet, A; Chast, F; Delmer, A; Legrand, O; Levy, V; Marie, JP; Marjanovic, Z; Rio, B; Vekhoff, A; Zittoun, R | 1 |
| Ell, C; Gossner, L; Hahn, EG; Keymling, J | 1 |
| Buxbaum, A; Georgopoulos, A; Graninger, W | 1 |
| Atchison, KP; Atwal, H; Higashitani, F; Hyodo, A; Kunugita, C; Maiti, SN; Micetich, RG; Nishida, K; Phillips, OA; Salama, SM; Spevak, P; Uji, T; Unemi, N | 1 |
| Allerberger, F; Feierl, G; Hirschl, A; Krause, R; Mittermayer, H; Reisinger, EC; Wendelin, I | 1 |
| Kays, MB | 1 |
| Bonafede, M; Bonomo, RA; Carias, LL; Hoyen, C; Hujer, AM; Hutton, R; Rice, LB | 1 |
| Bradley, SJ | 1 |
| Cross, JM; May, AK; McGwin, G; Melton, SM; Moser, SA; Rue, LW | 1 |
| Amicosante, G; Belloni, R; Bianchi, C; Lombardi, G; Luzzaro, F; Perilli, M; Toniolo, A; Zollo, A | 1 |
| Anstead, G; Blaser, M; Craig, F; Jorgensen, J; Patterson, T | 1 |
| Bauduer, F; Boiron, JM; Boulat, O; Cousin, T; Fegueux, N; Jourdan, E; Molina, L; Reiffers, J; Rigal-Huguet, F | 1 |
| Moland, ES; Thomson, KS | 1 |
| Batlle, M; Benlloch, L; Capote, FJ; Gutiérrez, M; Jarque, I; Julià, A; Lahuerta, JJ; Larrea, L; López, J; Palau, J; Pérez, C; Ramos, F; Rovira, M; Sanz, MA; Vázquez, L | 1 |
| Jones, RN; Mutnick, AH; Turner, PJ | 1 |
| Burgess, DS; Nathisuwan, S | 1 |
| Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH | 1 |
| Maier, A; Smolle-Jüttner, FM; Tomaselli, F | 1 |
| Choi, MK; Fish, DN; Husain, M; Jung, R | 1 |
| Blosser-Middleton, RS; Ge, Y; Karlowsky, JA; Sahm, DF; Wikler, MA | 1 |
| Goessens, WH; Gyssens, IC; Lemmens, N; Mouton, JW; Stearne, LE; van Boxtel, D | 1 |
| Høiby, N; Walther-Rasmussen, J | 1 |
| Bethel, CR; Bonomo, RA; Helfand, MS; Hujer, AM | 1 |
| Burgess, DS; Hall, RG | 1 |
| Bonnefoy, A; Delachaume, C; Dupuis-Hamelin, C; Fairley, M; Guitton, M; Lampilas, M; Seys, C; Stachyra, T; Steier, V | 1 |
| Arora, V; Prakash, SK; Prashad, R; Sharma, VK | 1 |
| Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
| Capparelli, FJ; Del Castillo, ME; Diaz, MF; Hlavnika, A; Leiguarda, R; Wainsztein, NA | 1 |
| Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
| Rice, LB | 1 |
| Avlamis, A; Daikos, GL; Markogiannakis, A; Papaparaskevas, J; Papapareskevas, J; Petrikkos, G; Stefanakos, G; Zissis, NP | 1 |
| Braga, AL; Burattini, MN; Jukemura, EM; Medeiros, EA; Pereira, CA | 1 |
| Correia, A; Domingues, MR; Domingues, P; Fonseca, F; Henriques, I; Saavedra, MJ; Samyn, B; Sarmento, AC; van Beeumen, J | 1 |
| Arora, J; Dogra, A; Rao, P; Taneja, N | 1 |
| Kulkarni, KP; Pal, P; Pal, RB; Venkatesh, V | 1 |
| Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Bulik, CC; Christensen, H; Nicolau, DP | 1 |
| De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X | 1 |
| Ge, Y; Livermore, DM; Mushtaq, S | 1 |
| Farrell, DJ; Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Ge, Y; Giske, CG; Karlsson, IM; Titelman, E | 1 |
| Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR | 1 |
| Benziger, D; Friedland, I; Hershberger, E; Miller, B; Trinh, M | 1 |
| Chandorkar, G; Gotfried, MH; Huntington, JA; Rodvold, KA; Umeh, O | 1 |
| Adams, CA; Cioffi, WG; Connolly, MD; Gregg, S; Heffernan, DS; Monaghan, SF; Stephen, A; Thakkar, RK | 1 |
| Chander, J; Garg, R; Gulati, N; Gupta, V; Krishnan, P; Kumarasamy, K | 1 |
| Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Andes, DR; Craig, WA | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Castanheira, M; Forrest, A; Friedrich, LV; Jones, RN; Mendes, RE; Nicasio, AM; Okusanya, OO; Steenbergen, JN; VanScoy, B | 1 |
| Adam, H; Baxter, M; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, P; Walkty, A; Zhanel, GG | 2 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, JN; Vanscoy, B | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 3 |
| Arakawa, S; Fujisawa, M; Miyake, H; Shigemura, K; Tanaka, K | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Dharuman, JG; Vasudevan, M | 1 |
| Adam, H; Chung, P; Denisuik, A; Gin, AS; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Lynch, JP; Rubinstein, E; Schweizer, F; Walkty, A; Zelenitsky, S; Zhanel, GG | 1 |
| Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Chandorkar, G; Hershberger, E; Krishna, G; Miller, B; Wooley, M | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Gautam, V; Kaur, R; Ray, P; Singhal, L | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 1 |
| Friedland, I; Hershberger, E; Lucasti, C; Miller, B; Solomkin, J; Steenbergen, J; Yankelev, S | 1 |
| Ambrose, PG; Bhavnani, SM; Castanheira, M; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Steenbergen, JN; VanScoy, BD | 1 |
| Aguilar, L; Gilsanz, F; Gimenez, MJ; Maseda, E | 1 |
| Bush, K; Bussell, B; Clugston, SL; Estabrook, M | 1 |
| Chandorkar, G; Hershberger, E; Krishna, G; Mouksassi, MS; Xiao, A | 1 |
| Frey, L; Maier, B; Suhr, A; Teupser, D; Vogeser, M; Zander, J; Zoller, M | 1 |
| Eckmann, C; Solomkin, J | 1 |
| Barie, PS; Collins, S; Eckmann, C; Friedland, I; Hershberger, E; Miller, B; Popejoy, M; Solomkin, J; Steenbergen, J; Yoon, M; Yuan, G | 1 |
| Bassetti, M; Righi, E | 1 |
| Lagarde, C; Mavridou, E; Melchers, MJ; Mouton, JW; Seyedmousavi, S; van Mil, AC | 1 |
| Darouiche, RO; Steenbergen, J; Umeh, O; Wagenlehner, FM; Yuan, G | 1 |
| Melchers, MJ; Mouton, JW; van Mil, AC | 1 |
| Cleveland, KO; Gelfand, MS | 1 |
| Al-Attas, A; Belal, F; El-Enany, N; Nasr, JJ | 1 |
| Skalweit, MJ | 1 |
| Nicolau, DP; Sutherland, CA | 2 |
| Huntington, JA; Miller, BW; Nicolau, DP; Xiao, AJ | 1 |
| Cho, JC; Estrada, SJ; Fiorenza, MA | 1 |
| Hirsch, EB; Liscio, JL; Mahoney, MV | 1 |
| Chahine, EB; Cogan, P; Fete, M; Sucher, AJ | 1 |
| Berrazeg, M; Broutin, I; Fournier, D; Jeannot, K; Loeffert, S; Ntsogo Enguéné, VY; Plésiat, P | 1 |
| Burnham, CA; Dubberke, ER; Gonzalez, MD; Hink, T; Wallace, MA | 1 |
| Bofarull, AM; Cantón, R; García-Castillo, M; Tato, M | 1 |
| Hussar, DA | 1 |
| Armstrong, ES; Farrell, DJ; Palchak, M; Steenbergen, JN | 1 |
| Bowker, KE; MacGowan, AP; Nicholls, D; Noel, AR; Tomaselli, SG | 1 |
| Fowler, RC; Geyer, CN; Hanson, ND; Hawkey, P; Johnson, JR; Johnston, B; Weissman, SJ | 1 |
| Cluck, D; Lewis, P; Moorman, J; Spivey, J; Stayer, B | 1 |
| Hsu, AJ; Tamma, PD; Tamma, SM | 1 |
| Geerlings, SE; Holleman, F; Schneeberger, C | 1 |
| Gonzales, JP; Heil, EL; Mehrotra, S; Nicolau, DP; Oliver, WD; Robinett, K; Saleeb, P | 1 |
| Bulman, ZP; Forrest, A; Friedrich, LV; Holden, PN; Kelchlin, P; Lenhard, JR; Soon, RL; Steenbergen, JN; Tsuji, BT | 1 |
| Scott, LJ | 1 |
| Boyd, D; Carpenter, M; Desruisseau, A; Janecko, N; Mangat, CS; Martz, SL; Mulvey, MR; Reid-Smith, RJ | 1 |
| Alkrouk, A; Buehrle, DJ; Chen, L; Clancy, CJ; Hao, B; Kreiswirth, BN; Nguyen, MH; Potoski, BA; Press, EG; Shields, RK | 1 |
| Bliss, C; Cloutier, DJ; Goldstein, EJ; Huntington, JA; Sakoulas, G; Steenbergen, JN; Umeh, O | 1 |
| Arya, A; Barber, KE; Hallesy, J; Rybak, MJ; Singh, NB; Smith, JR; Yim, J | 1 |
| Greenwood-Quaintance, KE; Karau, MJ; Kohner, PC; Patel, R; Schmidt-Malan, SM; Velez Perez, AL | 1 |
| Alverdy, J; Hershberger, E; Miller, B; Popejoy, MW; Steenbergen, JN | 1 |
| Aitken, SL; Bhatti, MM; DePombo, AM; Gettys, SC; Kontoyiannis, DP; Nicolau, DP; Nunez, CA; Tverdek, FP | 1 |
| Alidjanov, JF; Wagenlehner, FM | 1 |
| Antony, S; Dominguez, DC; Soto-Ruiz, E; Teleb, M | 1 |
| Ghazi, IM; Kuti, JL; Nicolau, DP; Quintiliani, R; Shore, E | 1 |
| McClain, D; Vickery, SB; Wargo, KA | 1 |
| Cies, JJ; Kuti, JL; Monogue, ML; Muhlebach, M; Nicolau, DP; Pettit, RS | 1 |
| Borgia, G; Gentile, I; Maraolo, AE | 1 |
| Algora-Weber, A; de la Calle-Pedrosa, N; Delgado-Iribarren, A; Gabán-Díez, Á; González-Jiménez, AI; Hernández-Tejedor, A; Martín-Vivas, A; Merino-Vega, CD; Ruiz de Luna-González, R; Temprano-Gómez, I | 1 |
| Bliss, CA; Cloutier, D; Hershberger, E; Huntington, JA; Kaye, KS; Miller, B; Paterson, DL; Popejoy, MW; Steenbergen, JN; Umeh, O | 1 |
| Armstrong, ES; Bliss, CA; Cloutier, DJ; Mikulca, JA; Steenbergen, JN | 1 |
| Baumert, P; Feihl, S; Gastmeier, P; Gebhardt, F; Gölz, H; Hamprecht, A; Kern, WV; Knobloch, J; Kola, A; Mischnik, A; Obermann, B; Peter, S; Querbach, C; Rohde, A; Seifert, H; Tacconelli, E; Willmann, M | 1 |
| Castón, JJ; De la Torre, Á; Ruiz-Camps, I; Sorlí, ML; Torre-Cisneros, J; Torres, V | 1 |
| Connor, KA | 1 |
| Goldstein, EJ; Kullar, R; Long, J; Popejoy, MW; Wagenlehner, FM; Yu, B | 1 |
| Crespo Casal, M; Martinez-Lamas, L; Nodar, A; Perez-Landeiro, A; Perez-Rodríguez, MT; Sousa Dominguez, A | 1 |
| Hamada, Y; Nicolau, DP; Thabit, AK | 1 |
| Burnham, CA; Crotty, MP; Gonzalez, MD; McMullen, AR; Ritchie, DJ; Wallace, MA | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Compain, F; Grohs, P; Kaibi, I; Lavollay, M; Mainardi, JL; Morand, P; Podglajen, I; Taieb, G | 1 |
| Bassetti, M; Castanheira, M; Duncan, LR; Pfaller, MA | 1 |
| Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR | 1 |
| Rademacher, J; Welte, T | 1 |
| Abbo, LM; Adachi, J; Aitken, SL; Araos, R; Arias, CA; Bonomo, RA; Jain, R; Lichtenberger, PN; Miller, WR; Munita, JM; Nigo, M; Perez, F; Rakita, R; Rosa, R; Shelburne, S; Shimose, LA; Tran, TT; Wanger, A | 1 |
| Álvarez Lerma, F; Gracia Arnillas, MP; Grau, S; Mico García, M; Muñoz Bermudez, R; Recasens, L; Sorli, L | 1 |
| Berenson, CS; Kurtzhalts, KE; Manohar, A; Mergenhagen, KA | 1 |
| Béraud, G; Bouchand, F; Canouï, E; Davido, B; Dinh, A; Duran, C; Ferry, T; Hénard, S; Kernéis, S; Lazaro, P; Lebeaux, D; Wolff, M; Wyplosz, B | 1 |
| Huntington, JA; Long, J; Popejoy, MW | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 3 |
| Bassetti, M; Castaldo, N; Givone, F; Peghin, M; Righi, E; Sartor, A | 1 |
| Adkin, R; Chaudhry, A; Hill, R; Hopkins, KL; Livermore, DM; Meunier, D; Mushtaq, S; Pike, R; Staves, P; Woodford, N | 1 |
| Ahir, H; Foo, J; Merchant, S; Prabhu, V; Sarpong, E | 1 |
| Borgia, G; Buonomo, AR; De Zottis, F; Di Renzo, G; Gentile, I; Maraolo, AE; Scotto, R | 1 |
| Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
| Cabot, G; Del Barrio-Tofiño, E; Fraile-Ribot, PA; Juan, C; Mulet, X; Oliver, A; Pérez, JL | 1 |
| Davido, B; de Truchis, P; Dinh, A; Salomon, J; Senard, O | 1 |
| Alatoom, A | 1 |
| Chesnel, L; Howland, K; Jacqueline, C | 1 |
| Grupper, M; Nicolau, DP; Sutherland, C | 1 |
| Mueller, BA; Shaw, AR | 1 |
| Flamm, RK; Huband, MD; Jones, RN; Riedel, S; Sader, HS | 1 |
| Borgia, G; Cascella, M; Corcione, S; Cuomo, A; De Rosa, FG; Gentile, I; Maraolo, AE; Nappa, S | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Sinkó, J | 1 |
| Chen, L; Kreiswirth, BN; MacVane, SH; Pandey, R; Steed, LL | 1 |
| Becker, K; Bletz, S; Idelevich, EA; Mellmann, A; Schaumburg, F | 1 |
| Bodro, M; Marco, F; Martínez, JA; Soriano, A; Xipell, M | 1 |
| Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
| Cheng, S; Clancy, CJ; Cooper, VS; Doi, Y; Haidar, G; Hao, B; Nguyen, MH; Philips, NJ; Potoski, BA; Press, EG; Shields, RK; Snyder, D | 1 |
| Livermore, DM; Mushtaq, S; Turner, SJ; Warner, M; Woodford, N | 1 |
| Bassetti, M; Castaldo, N; Givone, F; Lechiancole, A; Livi, U; Maiani, M; Pea, F; Peghin, M; Righi, E; Sartor, A | 1 |
| Lodise, TP; Natesan, S; Pai, MP | 1 |
| Lasco, TM; Ledesma, KR; Skoglund, E; Tam, VH | 1 |
| Cabot, G; Fraile-Ribot, PA; Juan, C; Martín-Pena, ML; Mulet, X; Oliver, A; Pérez, JL; Periañez, L | 1 |
| Arcenillas, P; Boix-Palop, L; Calbo, E; Cuchi, E; Dietl, B; Gómez, L; González de Molina, FJ; Nicolás, J; Sánchez, I | 1 |
| Chen, L; Clancy, CJ; Haidar, G; Hao, B; Kreiswirth, BN; Nguyen, MH; Pasculle, AW; Press, EG; Shields, RK | 1 |
| Bansal, N; Gopalakrishnan, R; Kumar D, S; Nambi, PS; Ramasubramanian, V; Sukhwani, KS | 1 |
| Hindler, JA; Humphries, RM; Magnano, P; Miller, SA; Tibbetts, R; Wong-Beringer, A | 1 |
| Arena, F; Bassetti, M; D'Andrea, MM; Di Pilato, V; Giani, T; Henrici De Angelis, L; Pollini, S; Rossolini, GM | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Monogue, ML; Nicolau, DP | 1 |
| Bodro, M; Fresco, L; Marco, F; Martínez, JA; Paredes, S; Soriano, A; Xipell, M | 1 |
| Bischoff, S; Ebert, M; Gerigk, M; Vogelmann, R; Walter, T | 1 |
| Fridrichová, M; Jakubů, V; Žemličková, H | 1 |
| Hakki, M; Lewis, JS | 1 |
| Allworth, AM; Legg, A; McCarthy, KL; Roberts, JA; Stewart, A; Wallis, SC | 1 |
| Chan, E; Hui, SW; Lau, SKP; Martelli, P; Teng, JLL; Woo, PCY | 1 |
| Bassetti, M; De Rosa, FG; Del Bono, V; Giacobbe, DR; Grossi, PA; Menichetti, F; Pea, F; Rossolini, GM; Tumbarello, M; Viale, P; Viscoli, C | 1 |
| Girotto, JE; Nicolau, DP; Rodriguez, BA | 1 |
| Blasi, F; Downey, DG; Elborn, JS; Gramegna, A; Millar, BC; Moore, JE | 1 |
| Bertrand, X; Bouiller, K; Bouxom, H; Fournier, D; Hocquet, D | 1 |
| Almirante, B; Arévalo, Á; Campany, D; Escolà-Vergé, L; Ferrer, R; Larrosa, N; Len, O; Los-Arcos, I; Nuvials, X; Pigrau, C; Viñado, B | 1 |
| Caro, L; Huntington, JA; Long, J; Xiao, AJ | 1 |
| Chaves, F; Lora-Tamayo, J; Orellana, MÁ; Recio, R; Viedma, E; Villa, J | 1 |
| Aguilar-Aguilar, G; Alós-Almiñana, M; Belda-Nacher, JF; Carbonell, JA; Ezquer-Garin, C; Ferriols-Lisart, R | 1 |
| Alessa, MA; Alhokail, M; Alhossan, A; Alkholief, MA; Almangour, TA; Tabb, DE | 1 |
| Dunn, A; Plant, AJ; Porter, RJ | 1 |
| Finklea, JD; Hollaway, R; Jain, R; Le, J; Lee, F; Lowe, K | 1 |
| Jones, AL; Lee, AC | 1 |
| De Wachter, E; Echahidi, F; Herpol, M; Peeters, C; Piérard, D; Van Dalem, A; Vandamme, P; Wybo, I | 1 |
| Cronin, K; Engler, C; Norton, R; Parsonson, F; Slack, A | 1 |
| Johnson, JR; Johnston, BD; Thuras, P | 1 |
| Jiménez-Delgado, JD; Monterrubio-Villar, J; Rodríguez-Garrido, S | 1 |
| Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Asensio, J; Ayestarán, I; Colomar, A; Delgado, O; Díaz-Cañestro, M; Fraile-Ribot, PA; López-Causapé, C; Maciá, M; Martin-Pena, ML; Mulet, X; Murillas, J; Novo, A; Nuñez, B; Oliver, A; Pérez, JL; Periañez, L; Riera, M; Torres, V | 1 |
| Ang, JY; Arrieta, AC; Bradley, JS; Caro, L; Johnson, MG; Larson, KB; Rhee, EG; Rizk, ML; Yang, S; Yu, B | 1 |
| Bonomo, RA; Chambers, HF; Chen, L; Domitrovic, TN; Evans, SR; Farmer, M; Fowler, VG; Hill, CB; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BN; Manca, C; Mediavilla, JR; Patel, R; Perez, F; Pitzer, KM; Tran, TTT; Wilson, BM | 1 |
| Dorn, C; Kees, F; Kratzer, A; Matzneller, P; Schießer, S; Schlossmann, J; Wulkersdorfer, B; Zeitlinger, M | 1 |
| Bidell, MR; Lodise, TP | 1 |
| Chan, E; Lau, SKP; Tse, CWS; Woo, PCY; Wu, AKL | 1 |
| Galega, R; Greene, JN; Lee, GC; Quilitz, R; Shurko, J; So, W | 1 |
| Bassetti, M; Montravers, P | 1 |
| Cheng, V; Dyer, J; Ingram, P; McWhinney, BC; Raby, E; Rawlins, M; Regli, A; Roberts, JA; Ungerer, JPJ | 1 |
| Eckmann, C; Lyon, S; Rojas, LJ | 1 |
| Floch, P; Gaudru, C; Guet-Revillet, H; Massip, C; Mathieu, C; Miaut, V; Oswald, E; Segonds, C | 1 |
| Dubois, V; Jayol, A; Kieffer, N; Nordmann, P; Ortiz De La Rosa, JM; Poirel, L | 1 |
| Hsueh, PR; Hsueh, SC; Huang, YT; Lee, YJ; Liao, CH; Tsuji, M | 1 |
| Henderson, A; McCarthy, KL; Paterson, DL; Tan, E | 1 |
| Artioli, S; Bassetti, M; Capone, A; Carannante, N; Castaldo, N; Cattelan, A; Cipriani, L; Coletto, D; Digaetano, M; Grossi, P; Losito, AR; Mastroianni, CM; Menichetti, F; Mussini, C; Nicolè, S; Peghin, M; Righi, E; Russo, A; Tascini, C; Tumbarello, M; Vena, A | 1 |
| Aoyama, N; Arakawa, S; Fujimoto, G; Kawahara, K; Kawahara, M; Rhee, EG; Sato, A; Yasuda, M; Yokokawa, R; Yoshinari, T | 1 |
| Feng, HP; Kakara, M; Larson, K; Rizk, ML; Shiomi, M; Yoshitsugu, H | 1 |
| Fujimoto, G; Fukuhara, T; Horiuchi, T; Mikamo, H; Miyasaka, Y; Monden, K; Rhee, EG; Shizuya, T; Yoshinari, T | 1 |
| Fernández Esgueva, M; Ferrer Cerón, I; García-Lechuz Moya, JM; López-Calleja, AI; Morilla Morales, E; Nuñez Medina, R; Rezusta López, A; Sahagún Pareja, J; Viñuelas Bayon, J | 1 |
| Basak, GW; Saran, O; Sulik-Tyszka, B; Wróblewska, MM | 1 |
| Arena, F; Cassetta, MI; Contorni, M; Henrici De Angelis, L; Maglioni, E; Marchetti, L; Novelli, A; Rossolini, GM | 1 |
| Ariza, J; Benavent, E; El Haj, C; Gómez-Junyent, J; Murillo, O; Rigo-Bonnin, R; Sierra, Y; Soldevila, L; Torrejón, B; Tubau, F | 1 |
| Duncan, LR; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
| Blázquez-Gamero, D; Brañas, P; Epalza, C; Flores, M; Grau, S; Martín-Cazaña, M; Olmedilla, M | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Di Bonaventura, G; Fiscarelli, E; Gherardi, G; Linardos, G; Pompilio, A | 1 |
| Aitken, E; Gould, IM; Hijazi, K; Joshi, C; Oggioni, MR; Zamudio, R | 1 |
| Humphries, RM; Spafford, K | 1 |
| Bonomo, RA; Evans, SR | 1 |
| Bradley, JS; Caro, L; Larson, KB; Patel, YT; Rhee, EG; Rizk, ML; Willavize, S | 1 |
| Aguilar, G; Alós, M; Carbonell, JA; Ezquer, C; Ferriols, R; Martínez-Castro, S; Navarro, D; Pastor, E | 2 |
| Chen, GJ; Chen, WT; Foo, J; Morel, C; Pan, SC; Wang, JT | 1 |
| Avery, LM; Nicolau, DP; Sutherland, CA | 1 |
| Akova, M; Albasanz-Puig, A; Araos, R; Bote, A; Brunel, AS; Calik, S; Carratalà, J; Del Pozo, JL; Drgona, L; García, E; Gomes, MZR; Gudiol, C; Hemmati, P; Herrera, F; Ibrahim, KY; Isler, B; Kanj, S; Kern, W; Maestro de la Calle, G; Manzur, A; Marin, JI; Márquez-Gómez, I; Martín-Dávila, P; Mikulska, M; Montejo, JM; Montero, M; Morales, HMP; Morales, I; Novo, A; Oltolini, C; Parody, R; Peghin, M; Puerta-Alcalde, P; Ruiz-Camps, I; Sipahi, OR; Tebe, C; Tilley, R; Yáñez, L | 1 |
| Nordmann, P; Ortiz de la Rosa, JM; Poirel, L | 1 |
| Baklouti, S; Concordet, D; Gandia, P; Guet-Revillet, H; Mane, C; Massip, C; Murris, M | 1 |
| Hoban, DJ; Lob, SH; Motyl, MR; Sahm, DF; Young, K | 1 |
| Ann Justo, J; Bookstaver, PB; Elizabeth Davis, S; Foster, R; Gould, A; Ham, J; Hucks, J; Nicolau, DP | 1 |
| Boulanger, B; Cizeau, F; Decousser, JW; Ducellier, D; Fourreau, F; Mercier-Darty, M; Mongardon, N; Podglajen, I; Potron, A; Royer, G | 1 |
| Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, P; Galán-Sánchez, F; González-Bello, C; Lence, E; Martínez-Guitián, M; Oliver, A; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
| Bou, G; Cabot, G; Cortes-Lara, S; Del Barrio-Tofiño, E; López-Causapé, C; Martínez-Martínez, L; Oliver, A; Sánchez-Diener, I; Zamorano, L | 1 |
| Papp-Wallace, KM | 1 |
| Abdel Hadi, H; Abu Jarir, S; Al-Maslamani, MA; Bonomo, RA; Dousa, KM; Eltai, NO; Hassan, AAI; Hujer, AM; Ibrahim, EB; Jass, J; Omrani, AS; Sid Ahmed, MA; Soderquist, B; Sultan, AA | 1 |
| Bonomo, RA; Davis, SL; Dhar, S; File, TM; Gerlach, AT; Kaye, KS; Olson, S; Patel, TS; Perez, F; Pogue, JM; Puzniak, LA; Veve, MP | 1 |
| Bruno, CJ; Butterton, JR; Huntington, JA; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Kalil, AC; Zavascki, AP | 1 |
| Flamm, RK; Pfaller, MA; Shortridge, D; Streit, JM | 1 |
| Lassig-Smith, M; Lipman, J; Pandey, S; Parker, SL; Roberts, JA; Sime, FB; Starr, T; Stuart, J; Wallis, SC | 1 |
| Chopra, A; Cies, JJ; Enache, A; Giliam, N; Low, T; Moore, WS | 1 |
| Martín-Asenjo, M; Martín-Guerra, JM | 1 |
| Chen, YH; Cheng, IL; Lai, CC; Tang, HJ | 1 |
| Dorn, C; Eberl, S; Nussbaumer-Pröll, AK; Reiter, B; Stimpfl, T; Zeitlinger, M | 1 |
| Barreto Gutierrez, L; De Bels, D; Gallerani, A; Honore, PM; Kaefer, K; Mugisha, A; Redant, S | 1 |
| Aso, S; Fushimi, K; Goto, H; Kaita, Y; Kojiro, M; Matsui, H; Nakajima, M; Yamaguchi, Y; Yasunaga, H | 1 |
| Freyre-Carrillo, C; García-Martín, S; Martínez Rubio, C; Prado-Montoro, CD; Rodríguez-Iglesias, MA; Ruiz-Aragón, J | 1 |
| Bruno, CJ; Kollef, MH; Réa-Neto, Á; Rhee, EG; Wunderink, RG | 1 |
| Lai, CC; Tang, HJ | 1 |
| Baillon-Plot, N; Bassetti, M; Charbonneau, C; Di Virgilio, R; Eckmann, C; Kongnakorn, T; Tichy, E | 1 |
| Bonomo, RA; Kaye, KS; Perez, F; Pogue, JM | 1 |
| Bassetti, M; Cattelan, A; Giacobbe, DR; Mussini, C; Vena, A | 1 |
| Ang, JY; Arrieta, A; Bradley, JS; Johnson, MG; Rhee, EG; Rizk, ML; Yu, B; Zhang, Z | 1 |
| Buonomo, AR; Gentile, I; Maraolo, AE; Mazzitelli, M; Torti, C; Trecarichi, EM | 1 |
| Carvalhaes, CG; Castanheira, M; Flamm, RK; Sader, HS | 1 |
| Alves, V; Cantón, R; Chaves, C; Diogo, J; Ferreira, R; García-Castillo, M; García-Fernández, S; Gonçalves, E; Melo-Cristino, J; Paixão, L; Pássaro, L; Pinto, MF; Ramalheira, E; Sancho, L; Silva, D; Vieira, AR | 1 |
| Karlowsky, JA; Kazmierczak, KM; Motyl, MR; Sahm, DF; Young, K | 1 |
| Buonomo, AR; Congera, P; Foggia, M; Gentile, I; Maraolo, AE; Parente, S; Scotto, R; Zappulo, E | 1 |
| Abdulhamid, I; Ang, JY; Molloy, L; Srivastava, R | 1 |
| Akyüz, S; Güdücüoğlu, H; Parlak, M | 1 |
| Carniel, E; Narvaez, GA; Perez, LRR | 1 |
| Millar, BC; Moore, JE; Moore, RE | 1 |
| Kharat, AS; Khobragade, K; Palwe, S; Periasamy, H; Veeraraghavan, B | 1 |
| Cabot, G; Fernández-Esgueva, M; Fraile-Ribot, PA; Huarte, R; López-Calleja, AI; Mulet, X; Oliver, A; Rezusta, A | 1 |
| Jain, M; Mahmoud, A; Nicolau, DP; Nutley, K; Rhodes, NJ; Scheetz, MH; Shah, A; Sutherland, C | 1 |
| Juhász, E; Katona, K; Kristóf, K; Melegh, S; O'Neall, D; Szabó, J; Tóth, Á; Urbán, E | 1 |
| Amore, D; Anile, M; Bassi, M; Cagnetti, S; Carillo, C; D'Agostino, FG; De Giacomo, T; Diso, D; Mantovani, S; Mottola, E; Pagini, A; Pecoraro, Y; Poggi, C; Pugliese, F; Rendina, EA; Russo, G; Vannucci, J; Venuta, F | 1 |
| Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z | 1 |
| Cayô, R; Cuba, GT; Gales, AC; Kiffer, CRV; Nicolau, DP; Nodari, CS; Pignatari, ACC; Rocha-Santos, G; Streling, AP | 2 |
| DePestel, DD; Karlowsky, JA; Lob, SH; Motyl, MR; Raddatz, J; Sahm, DF; Young, K | 1 |
| Al-Hasan, MN | 1 |
| Manning, L; Naicker, S; Pandey, S; Raby, E; Roberts, JA; Sime, FB; Wallis, SC | 1 |
| Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H | 1 |
| Ang, JY; Arrieta, AC; Feng, EH; Johnson, MG; Larson, KB; Rhee, EG; Rizk, ML; Yu, B; Zhang, Z | 1 |
| Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E | 1 |
| Concordet, D; Delmas, C; Gandia, P; Georges, B; Jourdan, G; Mané, C; Marcheix, B; Porterie, J; Ruiz, S; Verwaerde, P | 1 |
| Cantón, R; Gomes, R; Martins-Oliveira, I; Pérez-Viso, B; Pina-Vaz, C; Quintas, S; Rodrigues, AG; Silva-Dias, A | 1 |
| Arends, SJR; Duncan, LR; Flamm, RK; Pfaller, MA; Shortridge, D; Streit, JM | 1 |
| Canovas, J; Chau, F; Fantin, B; Le Monnier, A; Lefort, A; Petitjean, G | 1 |
| Carvalhaes, CG; Duncan, LR; Flamm, RK; Sader, HS; Shortridge, D | 1 |
| Bisanti, A; Diaz, E; Martin-Loeches, I; Rodriguez, A | 1 |
| Araj, GF; Berjawi, DM; El Beayni, NK; Musharrafieh, U | 1 |
| Bidell, MR; Lodise, TP; O'Donnell, JN | 1 |
| Abou Chakra, M; Dellis, A; Moussa, M; Moussa, Y; Papatsoris, A | 1 |
| Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; González-Bello, C; Lasarte-Monterrubio, C; Lence, E; Martínez-Guitián, M; Oliver, A; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
| Anguita-Santos, F; Aznarte-Padial, MP; Borreguero, I; Castón, JJ; Corzo-Delgado, JE; Esteban-Moreno, MÁ; Herrero-Rodríguez, C; Jiménez-Aguilar, P; López-Cárdenas, S; Maldonado, N; Martín-Aspas, A; Martínez-Marcos, FJ; Ojeda-Burgos, G; Palacios-Baena, ZR; Praena-Segovia, J; Retamar, P; Rodríguez-Baño, J; Rosso-Fernández, CM; Valiente de Santis, L | 1 |
| Carvalhaes, CG; Castanheira, M; Doyle, TB; Sader, HS; Streit, JM | 1 |
| Forland, SC; Guerrero-Wooley, RL; Hino, G; Park, SH; Winans, SA | 1 |
| Avdic, E; Beisken, S; Bergman, Y; Cosgrove, SE; Posch, AE; Sharara, SL; Simner, PJ; Tamma, PD | 1 |
| Edpuganti, V; Hall, RG; Kallem, RR; Putnam, WC; Subramaniyan, I | 1 |
| Bookstaver, PB; Bouchard, J; Gould, AP; Hucks, J; Justo, JA; Nelson, D; Nicolau, D; O'Neal, M; Sheffield, M | 1 |
| Bruno, CJ; Feng, HP; Fiedler-Kelly, J; Gao, W; Patel, YT; Zhang, Z | 1 |
| Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
| De Ponti, F; Gatti, M; Giannella, M; Raschi, E; Viale, P | 1 |
| Bassetti, M; Giacobbe, DR; Pelosi, P; Robba, C; Vena, A | 1 |
| Bacca, E; Bedini, A; Bianco, V; Cuomo, G; Franconi, I; Meschiari, M; Mussini, C; Orlando, G | 1 |
| Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Galán-Sánchez, F; González-Bello, C; Lasarte-Monterrubio, C; Oliver, A; Rodiño-Janeiro, BK; Rodríguez-Iglesias, M; Vázquez-Ucha, JC | 1 |
| Alves, V; Bou, G; Cantón, R; Cercenado, E; Chaves, C; Delgado-Valverde, M; Díaz-Regañón, J; Diogo, J; Ferreira, R; García-Castillo, M; García-Fernández, S; Gonçalves, E; Hernández-García, M; López-Mendoza, D; Melo-Cristino, J; Oliver, A; Paixão, L; Pássaro, L; Pinto, MF; Pitart, C; Ramalheira, E; Rodríguez-Lozano, J; Romano, J; Sancho, L; Silva, T; Tormo, N; Vieira, AR | 1 |
| Cohen, L; Finklea, JD; Jain, R; Nolan, PJ; Smith, TT | 1 |
| Cisera, K; Hughes, C; Rogers, B; Taylor, L; Xie, O | 1 |
| Asensio-Martín, MJ; Balandin, B; Ballesteros, D; Chicot, M; Fernández-Simón, I; Iranzo, R; López-Vergara, L; Martínez-Sagasti, F; Pérez-Pedrero, MJ; Pintado, V; Rodríguez-Serrano, D; Royuela, A; Ruiz de Luna, R; Sancho-González, M; Silva, A; Soriano-Cuesta, C | 1 |
| De Ponti, F; Gatti, M; Raschi, E | 1 |
| Bruno, C; Carmelitano, P; Castanheira, M; De Anda, C; Huntington, JA; Johnson, MG; Motyl, M; Rhee, EG; Yu, B | 1 |
| Abdelraouf, K; Gill, CM; Nicolau, DP | 1 |
| Carvalhaes, CG; Flamm, RK; Shortridge, D; Streit, JM | 1 |
| Lipman, J; Pandey, S; Parker, SL; Roberts, JA; Sime, FB; Stuart, J; Wallis, SC | 1 |
| Khan, S; Phe, K; Tam, VH | 1 |
| Arcay, RM; Cantón, R; Castillo, FJ; Cercenado, E; Cisterna, R; Díaz-Regañón, J; Gálvez-Benítez, L; González Romo, F; Hernández-Cabezas, A; López-Mendoza, D; Loza, E; Rodríguez-Lozano, J; Suárez-Barrenechea, AI; Tubau, F | 1 |
| Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Young, K | 1 |
| Baccani, I; Bartalesi, F; Bartoloni, A; Borchi, B; Bresci, S; Cavallo, A; Ottino, L; Rossolini, GM | 1 |
| Garello, P; Livermore, DM; Mushtaq, S; Vickers, A; Woodford, N | 1 |
| Sivashanmugam, K; Srivastava, P | 1 |
| Kullappan, M; Mallavarapu Ambrose, J; Surapaneni, KM | 1 |
| Collings, H; Dillon, R; Enstone, A; Palmer, T; Puzniak, L | 1 |
| Bernardi, M; Castagna, A; Castiglion, B; Ciceri, F; Clerici, D; Corti, C; Farina, F; Giglio, F; Greco, R; Liberatore, C; Lorentino, F; Mastaglio, S; Oltolini, C; Pavesi, F; Peccatori, J; Ripa, M; Scarpellini, P; Tassan Din, C | 1 |
| Murri, R; Sacco, E | 1 |
| Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E | 1 |
| Betthauser, KD; Kollef, MH; Lizza, BD; Micek, ST; Ritchie, DJ | 1 |
| Ayala-Figueroa, RI; Gastélum-Acosta, M; Guerrero-Estrada, P; Martínez-Miranda, R; Osuna-Álvarez, LE | 1 |
| Chatfield, MD; Harris, PNA; Littleford, R; Paterson, DL; Stewart, AG | 1 |
| Bauer, T; Berbescu, S; Bouchand, F; Davido, B; de Laroche, M; Dinh, A; Duran, C; Matt, M; Nich, C; Noussair, L; Pagis, V; Rempenault, C; Rottman, M; Salomon, E | 1 |
| Garcia, JA; Liang, SY; Long, B; Matlock, A; Moussavi, K | 1 |
| Ariano, R; Bassetti, M; Baxter, M; Borgia, S; Cervera, C; Dhami, R; Dow, G; Dube, M; Irfan, N; Karlowsky, JA; Kosar, J; Savoie, M; Tessier, JF; Walkty, A; Zhanel, GG; Zvonar, R | 1 |
| Barrio-Tofiño, ED; Cortes-Lara, S; López-Causapé, C; Oliver, A | 1 |
| Akrich, B; Amode, A; Berthelot, A; Boutoille, D; Castan, B; Levy-Bachelot, L; Mackosso, C; Mathis, L; Mootien, J; Ruimy, R; Ruiz, F; Timsit, JF | 1 |
| Al Jalali, V; Dorn, C; Kratzer, A; Lackner, E; Matzneller, P; Österreicher, Z; Taubert, M; Wölfl-Duchek, M; Wulkersdorfer, B; Zeitlinger, M | 1 |
| Cazorla-Poderoso, L; Huarte-Lacunza, R; Larrodé-Leciñena, I; López-Calleja, AI; Magallón-Martínez, A; Martínez-Álvarez, RM; Pereira-Blanco, O; Pérez-Moreno, M; Pinilla-Rello, A | 1 |
| Daragon, B; Fournier, D; Jeannot, K; Plésiat, P | 1 |
| Cantón, R; García-Castillo, M; García-Fernández, S; Hernández-García, M; Pássaro, L | 1 |
| Baere, S; Croubels, S; Devreese, M; Rutjens, S | 1 |
| Bruno, CJ; Butterton, JR; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Martin-Loeches, I; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wolf, DJ; Wunderink, RG; Yu, B | 1 |
| Hsueh, PR; Jean, SS; Ko, WC; Lee, YL; Liu, PY; Lu, MC | 1 |
| Bremmer, DN; Kline, EG; Nicolau, DP; Shah, S; Shields, RK | 1 |
| DePestel, DD; DeRyke, CA; Garrison, MW; Harris, KA; Moise, PA; Pfaller, MA; Sader, HS; Shortridge, D | 1 |
| Horcajada, JP; López Montesinos, I; Montero, M; Sorlí, L | 1 |
| Basu, S; Bruno, CJ; De Anda, C; Feng, HP; Gao, W; Huntington, JA; Jensen, E; Kollef, MH; Rhee, EG; Shorr, AF; Yu, B; Zhang, Z | 1 |
| Carvalhaes, CG; Castanheira, M; Sader, HS; Shortridge, D | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
| Aitken, SL; Heil, EL; Monogue, ML; Pogue, JM | 1 |
| Adalia, R; Aguilar, G; Azanza, JR; Barberán, J; Borges, M; Bou Arévalo, G; Cardinal-Fernández, P; Estella, A; Fernández Gómez, J; Ferrer, R; González de Molina, FJ; León López, R; LLinares Mondéjar, P; Marco, F; Maseda, E; Mensa, J; Oliver, A; Pasquau, J; Poliakova, Y; Rascado, P; Robles Marcos, MS; Salavert, M; Serrano García, R; Soriano, A | 1 |
| Arend, LNVS; Bail, L; Ito, CAS; Nogueira, KDS; Tuon, FF | 1 |
| Angulo-Brunet, A; Campillo, N; Domene-Ochoa, S; Ferrer-Alapont, L; Grau, S; Horcajada, JP; López-Causapé, C; Luque, S; Montero, MM; Oliver, A; Padilla, E; Prim, N; Sorlí, L | 1 |
| Alcalde-Rico, M; Arias, CA; García, P; Khan, A; Martínez, JRW; Miller, WR; Moreno, MV; Munita, JM; Olivares-Pacheco, J; Rivas, L; Rojas, P; Wozniak, A | 1 |
| Chen, WT; DeRyke, CA; Kazmierczak, KM; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Caldwell, B; Hamprecht, A; Henriksen, AS; Longshaw, C; Thelen, P; Yamano, Y | 1 |
| Meesing, A; Sribenjalux, W; Wonglakorn, L | 1 |
| Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-Pérez, B; Fraile-Ribot, PA; Gato, E; González-Bello, C; Guijarro-Sánchez, P; Gutiérrez-Urbón, JM; Lasarte-Monterrubio, C; Oliver, A; Oviaño, M; Ruedas-López, A; Vallejo, JA; Vázquez-Ucha, JC; Velasco, D | 1 |
| Attou, R; Barreto Gutierrez, L; Boer, W; De Bels, D; Gallerani, A; Honore, PM; Kaefer, K; Moorthamers, S; Preseau, T; Redant, S | 1 |
| Bruno, CJ; Butterton, JR; Gates, D; Huntington, JA; Jensen, EH; Kivistik, Ü; Kollef, MH; Lin, G; Martin-Loeches, I; Motyl, M; Nováček, M; Réa-Neto, Á; Rhee, EG; Shime, N; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Bourguignon, L; Dheyriat, L; Ferry, T; Goutelle, S; Perpoint, T | 1 |
| Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS | 1 |
| Cabot, G; Gomis-Font, MA; Juan, C; López-Argüello, S; Moyá, B; Oliver, A; Zamorano, L | 1 |
| Al Musawa, M; Alattas, M; Alfahad, W; Alfozan, A; Alghamdi, A; Alhameed, AF; Aljabri, A; Almangour, TA; Almohaizeie, A; Almuhisen, S; Alraddadi, BM; AlShahrani, FS; Binkhamis, KM; Damfu, N; Khuwaja, M; Qutub, M | 1 |
| Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Al-Alawi, MM; Ali, HE; Almutairi, AF; AlTurki, R; Bahabri, NM; Janah, SS; Khalil, S; Qutub, MO; Tashkandi, WA | 1 |
| Carratalà, J; Cuervo, G; González Laguna, M; Llop Talaveron, J; Padullés, A; Pérez-Recio, S; Ronda, M; Soldevila-Boixader, L; Tubau Quintano, MF | 1 |
| Csékó, AB; Gál, J; Hermann, C; Iványi, ZD; Mogyoródi, B | 1 |
| Chew, KL; Leong, Q | 1 |
| Candel, FJ; González Del Castillo, J; Julián Jiménez, A; Matesanz, M | 1 |
| DeRyke, CA; Hilbert, DW; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Wong, MT; Young, K | 1 |
| Annane, D; Bonten, MJM; Carneiro, J; Deja, M; Estevez, F; Harbarth, S; Jereb, M; Jorens, PG; Lawrence, C; Rothbart, A; Schedler, D; Seme, K; Šifrer, F; Spöhr, F; Tomič, V; van Duijn, PJ; Verbrugghe, W | 1 |
| Ju, YG; Lee, HJ; Lee, MG; Sohn, JW; Yim, HS; Yoon, YK | 1 |
| Benítez-Cano, A; Grau, S; Luque, S; Navarrete-Rouco, ME; Roberts, JA; Sorlí, L | 1 |
| Cruz-López, F; Garza-González, E; Maldonado-Garza, HJ; Martínez-Meléndez, A; Morfin-Otero, R; Rodriguez-Noriega, E | 1 |
| Bassetti, M; Bruno, CJ; Castanheira, M; Huntington, JA; Jensen, EH; Johnson, MG; Motyl, M; Paterson, DL; Wolf, DJ; Yu, B | 1 |
| Antonelli, A; Brenciani, A; Brescini, L; Castelletti, S; Cirioni, O; D'Achille, G; Di Pilato, V; Fioriti, S; Giacometti, A; Giani, T; Giovanetti, E; Masucci, A; Mingoia, M; Morroni, G; Rossolini, GM | 1 |
| Carvalhaes, CG; Castanheria, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
| Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Oliver, A; Rumbo-Feal, S; Vázquez-Ucha, JC | 1 |
| Castanheira, M; Collingsworth, TD; DeVries, S; Doyle, TB; Hubler, CM; Mendes, RE | 1 |
| Gillani, SW; Hussain, MW; Mahmood, RK; Rathore, HA; Saeed, MW; Vippadapu, P | 1 |
| Bensaci, M; Bruno, CJ; Chen, G; Chen, X; Du, X; Fan, J; Huntington, JA; Johnson, MG; Sun, F; Sun, Y; Wang, H; Wang, Y | 1 |
| Castanheira, M; Chen, WT; Pfaller, M; Shortridge, D; Streit, J; Tulloch, M | 1 |
| Antonelli, A; Cherubini, S; D'Andrea, MM; Perilli, M; Piccirilli, A; Rossolini, GM | 1 |
| Bruno, CJ; De Anda, C; Feng, HP; Fiedler-Kelly, J; Gao, W; Patel, YT; Rhee, EG; Zhang, Z | 1 |
| Abbara, D; Afaneh, L; Al Duhailib, Z; Al Qahtani, MM; Al Sulaiman, K; Aldhayyan, N; Askar, G; Dyab, N; Hakeam, HA; Islami, M; Mansour, R | 1 |
| Bachta, KER; Bertucci, HK; Brunzelle, JS; Gatesy, SWM; Hauser, AR; Lebrun-Corbin, M; Minasov, G; Ozer, EA; Pincus, NB; Rosas-Lemus, M; Satchell, KJF; Shuvalova, LA | 1 |
| Gehlot, P; P, H | 1 |
| Cheng, B; Guo, P; Jia, P; Xu, Y; Yang, Q; Zhang, H; Zhu, Y | 1 |
| Bruno, C; Dillon, RJ; Khankhel, ZS; Puzniak, L; Thosar, M | 1 |
| Anda, C; Bruno, CJ; Feng, HP; Fiedler-Kelly, J; Gao, W; Johnson, MG; Patel, YT; Rhee, EG; Zhang, Z | 1 |
| Haines, RR; Hammer, KA; Putsathit, P; Tai, AS | 1 |
| Alekseeva, I; DeRyke, CA; Estabrook, MA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Attwood, M; Chavan, R; MacGowan, A; Muller, AE; Noel, A; Periasamy, H; Van den Berg, S | 1 |
| Maseda, E; Suárez de la Rica, A | 1 |
| Aiello, TF; Chumbita, M; Garcia-Vidal, C; Lopera-Mármol, C; Monzo-Gallo, P; Puerta-Alcalde, P | 1 |
| Baretta, V; Calore, E; Carraro, F; Cesaro, S; Colombini, A; Meazza, C; Muggeo, P; Onofrillo, D; Perruccio, K; Rosaria D'Amico, M; Zama, D | 1 |
| Gill, CM; Nicolau, DP | 1 |
| Bruno, CJ; Huntington, JA; Jensen, EH; Kollef, MH; Martin-Loeches, I; Timsit, JF; Wunderink, RG; Yu, B | 1 |
| Alekseeva, I; DeRyke, CA; Hawser, SP; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH | 1 |
| Böhringer, N; Horst, J; Hübner, J; Kappler, M; Kolberg, L; Kresna, IDM; Liu, Y; Marner, M; Mettal, U; Meyer-Bühn, M; Mihajlovic, S; Schäberle, TF; von Both, U; Wang, L | 1 |
| Carvalho, TN; Deglmann, RC; França, PHC; Hille, D; Kobs, VC; Melo, LH | 1 |
| Amara, M; Barraud, O; Bastide, M; Bernabeu, S; Bille, E; Bonnin, RA; Brun, CL; Cattoir, V; Corvec, S; d'Epenoux, LR; Degand, N; Dortet, L; Emeraud, C; Farfour, E; Fihman, V; Grillon, A; Guillard, T; Isnard, C; Jacquier, H; Janvier, F; Jousset, AB; Laurent, F; Lemonnier, A; Lomont, A; Merens, A; Mizrahi, A; Plouzeau, C; Ranc, AG; Soismier, N; Yin, N; Zahar, JR | 1 |
| Cabot, G; Khajehpour, M; Kim, K; Mark, BL; Oliver, A | 1 |
| Jia, P; Xu, Y; Yang, Q; Yu, W; Zhang, H; Zhu, Y | 1 |
| Arends, SJR; Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Akrich, B; DeRyke, CA; Hawser, SP; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Aja-Macaya, P; Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-González, A; Galán-Sánchez, F; González-Mayo, E; Guijarro-Sánchez, P; Lada-Salvador, P; Lasarte-Monterrubio, C; Martínez-Guitián, M; Muíño-Andrade, M; Oliver, A; Rodríguez-Iglesias, M; Rumbo-Feal, S; Vázquez-Ucha, JC; Vela-Fernández, R | 1 |
| Bogiel, T; Grabowska, M; Sękowska, A | 1 |
| Bensaci, M; Bruno, CJ; De Anda, C; Dementieva, N; Huntington, JA; Jackson, CA; Johnson, MG; Lonchar, J; Newland, J; Popejoy, MW; Rhee, EG; Su, FH | 1 |
| Hsueh, PR; Lee, YL | 1 |
| Hsueh, PR; Ko, WC; Lee, YL | 1 |
| Fujimori, T; Hagiya, H; Higashikage, A; Iio, K; Kakehi, A; Minabe, H; Okura, M; Otsuka, F; Yokoyama, Y | 1 |
| Ishizawa, T; Kimura, K; Kinoshita, M; Kubo, S; Nishio, K; Ohira, G; Okada, T; Shinkawa, H; Shirai, D; Tanaka, S; Tani, N; Tauchi, J | 1 |
| Faurholt-Jepsen, D; Jensen, PØ; Johansen, HK; Katzenstein, TL; Kolpen, M; Pressler, T; Qvist, T | 1 |
| Agyeman, AA; Boyce, JD; Bulitta, JB; Cortés-Lara, S; Figuerola, J; Fraile-Ribot, P; Franklyn, ERT; Gomis-Font, MA; Landersdorfer, CB; Lang, Y; Lee, WL; López-Causapé, C; Lucas, DD; Nation, RL; Oliver, A; Rogers, KE; Zhang, Y; Zhou, J | 1 |
| Abbott, IJ; Chang, CC; Dennison, A; Kostoulias, X; Peleg, AY; Spelman, DW; Wisniewski, J; Zisis, H | 1 |
| Al Musawa, M; Alanazi, MQ; Alassiri, D; Alfahad, W; Alghaith, J; Alharbi, A; Aljefri, D; Aljurbua, A; Almangour, TA; Almohaizeie, A; Almuhisen, S; Alsowaida, YS; Damfu, N; Ghonem, L; Khormi, Y | 1 |
| Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR | 1 |
50 review(s) available for tazobactam and cephalosporin c
| Article | Year |
|---|---|
Piperacillin/tazobactam in the treatment of polymicrobial infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Cephalosporins; Drug Combinations; Drug Resistance, Microbial; Humans; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1994 |
Role of newer broad-spectrum beta-lactam and fluoroquinolone antibiotics in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Carbapenems; Cephalosporins; Child; Child, Preschool; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Molecular Structure; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Ticarcillin | 1996 |
Role of pharmacodynamics in designing dosage regimens for beta-lactams.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Dose-Response Relationship, Drug; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2003 |
Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum beta-lactamases.
Topics: beta-Lactamases; Cefotaxime; Cephalosporins; Clavulanic Acid; Drug Resistance, Bacterial; Enterobacteriaceae; Enzyme Inhibitors; Gene Transfer, Horizontal; Monobactams; Penicillanic Acid; Penicillins; Phylogeny; Sulbactam; Tazobactam | 2004 |
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Enzyme Inhibitors; Fever; Humans; Neutropenia; Penicillanic Acid; Penicillins; Quality Assurance, Health Care; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2006 |
Antimicrobial resistance in gram-positive bacteria.
Topics: Animals; beta-Lactamase Inhibitors; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enterococcus faecalis; Gastrointestinal Tract; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Methicillin Resistance; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin Resistance | 2006 |
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2014 |
Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Combinations; Enzyme Inhibitors; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2014 |
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2015 |
Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.
Topics: Administration, Intravenous; Animals; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2015 |
Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Approval; Drug Resistance, Bacterial; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam; United States; United States Food and Drug Administration | 2015 |
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Randomized Controlled Trials as Topic; Tazobactam | 2015 |
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Bacterial; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2015 |
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Drug Resistance, Bacterial; Humans; Intraabdominal Infections; Mice; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2015 |
New drugs 2015, part 3.
Topics: Acids, Carbocyclic; Benzoxazines; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cephalosporins; Cyclopentanes; Drug Approval; Drug Combinations; Drug Therapy; Glucagon-Like Peptides; Guanidines; Humans; Imidazoles; Immunoglobulin Fc Fragments; Interferon-beta; Isoquinolines; Penicillanic Acid; Polyethylene Glycols; Pyridines; Quinuclidines; Recombinant Fusion Proteins; Tazobactam; Triazoles; United States; United States Food and Drug Administration | 2015 |
Ceftolozane-tazobactam: A new-generation cephalosporin.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Chemistry, Pharmaceutical; Clinical Trials as Topic; Humans; Penicillanic Acid; Tazobactam | 2015 |
Febrile urinary tract infections: pyelonephritis and urosepsis.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Diabetes Complications; Fever; Humans; Immunocompromised Host; Levofloxacin; Penicillanic Acid; Pyelonephritis; Randomized Controlled Trials as Topic; Risk Factors; Sepsis; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2016 |
Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Humans; Intraabdominal Infections; Multicenter Studies as Topic; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2016 |
Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Humans; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2016 |
[New antibiotics - standstill or progress].
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Ceftaroline; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Resistance, Multiple, Bacterial; Ephedrine; Humans; Macrolides; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Penicillanic Acid; Phenobarbital; Staphylococcal Infections; Tazobactam; Theophylline; Triazoles | 2017 |
Antibiotic Dosing in Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Critical Illness; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Renal Replacement Therapy; Sepsis; Tazobactam; Thienamycins | 2017 |
Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Critical Illness; Disease Management; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Intensive Care Units; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Tazobactam; Treatment Outcome | 2017 |
[Clinical aspects of severe infections caused by antibiotic-resistant Gram-negative bacteria. The Empire strikes back?]
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam | 2017 |
Ceftolozane/tazobactam: place in therapy.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Off-Label Use; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2018 |
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Tazobactam; Treatment Outcome | 2018 |
Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
Topics: Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Prognosis; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2018 |
Suboptimal Clinical Response Rates with Newer Antibiotics Among Patients with Moderate Renal Impairment: Review of the Literature and Potential Pharmacokinetic and Pharmacodynamic Considerations for Observed Findings.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Glomerular Filtration Rate; Humans; Kidney Diseases; Tazobactam; Treatment Outcome | 2018 |
The ideal patient profile for new beta-lactam/beta-lactamase inhibitors.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cephalosporins; Clinical Trials as Topic; Drug Combinations; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Tazobactam | 2019 |
The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials.
Topics: Cephalosporins; Humans; Intraabdominal Infections; Randomized Controlled Trials as Topic; Tazobactam; Urinary Tract Infections | 2020 |
Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam; Urinary Tract Infections | 2020 |
Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review.
Topics: Cephalosporins; Continuous Renal Replacement Therapy; Humans; Obesity; Tazobactam | 2020 |
Approach to the Treatment of Patients with Serious Multidrug-Resistant Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Pharmacotherapeutic advances for recurrent urinary tract infections in women.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Beverages; Ceftazidime; Cephalosporins; Drug Combinations; Female; Fosfomycin; Humans; Recurrence; Secondary Prevention; Tazobactam; Urinary Tract Infections; Vaccinium macrocarpon | 2020 |
Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature.
Topics: Adult; Aged; Anti-Bacterial Agents; Area Under Curve; beta-Lactamase Inhibitors; Cephalosporins; Drug Combinations; Drug Monitoring; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Young Adult | 2020 |
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftaroline; Ceftazidime; Cephalosporins; Cyclooctanes; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Public Health; Sepsis; Tazobactam | 2020 |
Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Real-world use of ceftolozane/tazobactam: a systematic literature review.
Topics: Cephalosporins; Comorbidity; Critical Illness; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Urinary Tract Infections | 2021 |
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin | 2021 |
New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Design; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Sisomicin; Tazobactam; Tetracyclines | 2021 |
Ceftolozane-tazobactam: When, how and why using it?
Topics: Anti-Bacterial Agents; Cephalosporins; Colistin; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Ceftolozane-tazobactam in nosocomial pneumonia.
Topics: Adult; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pseudomonas Infections; Tazobactam | 2022 |
Efficacy and
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Tazobactam | 2022 |
A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2022 |
Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR).
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Communicable Diseases; Humans; Tazobactam | 2022 |
Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2022 |
New treatments for multidrug-resistant non-fermenting Gram-negative bacilli Infections.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2022 |
46 trial(s) available for tazobactam and cephalosporin c
| Article | Year |
|---|---|
Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
Topics: Anti-Infective Agents; Cefepime; Cephalosporins; Drug Therapy, Combination; Fever; Humans; Neutropenia; Penicillanic Acid; Pilot Projects; Piperacillin; Prognosis; Prospective Studies; Tazobactam | 1998 |
Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Fever; Hematologic Neoplasms; Humans; Multivariate Analysis; Neutropenia; Opportunistic Infections; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 1998 |
Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents; Bacteremia; Bacterial Infections; Case-Control Studies; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Fever of Unknown Origin; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Tazobactam; Tobramycin; Vancomycin | 1999 |
Antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): a prospective randomized clinical trial.
Topics: Antibiotic Prophylaxis; Cefotaxime; Cephalosporins; Endoscopy; Enteral Nutrition; Enzyme Inhibitors; Female; Gastrostomy; Humans; Incidence; Intubation, Gastrointestinal; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Surgical Wound Infection; Tazobactam | 1999 |
A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Cefpirome; Cephalosporins; Enzyme Inhibitors; Female; Fever; France; Hematologic Neoplasms; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2001 |
Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2002 |
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2003 |
Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Middle Aged; Penicillanic Acid; Tazobactam; Young Adult | 2012 |
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cephalosporins; Female; Human Experimentation; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Plasma; Tazobactam; Time Factors; Young Adult | 2012 |
Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.
Topics: Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Intraabdominal Infections; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome | 2014 |
Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Penicillanic Acid; Renal Insufficiency; Tazobactam; Young Adult | 2015 |
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Intraabdominal Infections; Male; Metronidazole; Middle Aged; Penicillanic Acid; Prospective Studies; Tazobactam; Treatment Outcome; Young Adult | 2015 |
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Cephalosporins; Double-Blind Method; Drug Administration Schedule; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2015 |
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Pneumonia; Tazobactam; Young Adult | 2016 |
In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteroides; Bacteroides fragilis; Bacteroides Infections; Cephalosporins; Drug Therapy, Combination; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intraabdominal Infections; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2016 |
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Double-Blind Method; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2016 |
Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Female; Humans; Intraabdominal Infections; Male; Metronidazole; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2016 |
Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Lung; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Patient Safety; Penicillanic Acid; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Tazobactam | 2016 |
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Double-Blind Method; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome; Urinary Tract Infections; Young Adult | 2017 |
Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Cephalosporins; Dose-Response Relationship, Drug; Drug Administration Schedule; Enterobacteriaceae Infections; Female; Follow-Up Studies; Humans; Injections, Intravenous; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Recurrence; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2016 |
Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Penicillanic Acid; Renal Insufficiency; Tazobactam; Treatment Outcome; Urinary Tract Infections; Young Adult | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Diabetes Mellitus; Female; Humans; Intraabdominal Infections; Levofloxacin; Male; Metronidazole; Middle Aged; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2017 |
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.
Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Intraabdominal Infections; Male; Tazobactam; Urinary Tract Infections | 2018 |
The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Male; Middle Aged; Pyelonephritis; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2019 |
Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bayes Theorem; Cephalosporins; Female; Humans; Intraabdominal Infections; Japan; Male; Middle Aged; Models, Statistical; Tazobactam; Urinary Tract Infections; Young Adult | 2019 |
The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
Topics: Aged; Anti-Bacterial Agents; Bacteria; Cephalosporins; Female; Humans; Intraabdominal Infections; Japan; Male; Metronidazole; Middle Aged; Tazobactam; Treatment Outcome | 2019 |
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Female; Humans; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Tazobactam; Treatment Outcome | 2019 |
Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Cephalosporins; Child; Clinical Trials as Topic; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Infant; Infant, Newborn; Infant, Premature; Injections, Intravenous; Male; Preoperative Care; Tazobactam | 2021 |
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Critical Illness; Humans; Lung; Pneumonia; Tazobactam | 2020 |
Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Gram-Negative Bacterial Infections; Humans; Male; Tazobactam | 2020 |
Development and validation of a quantitative LC-MS/MS method for the simultaneous determination of ceftolozane and tazobactam in human plasma and urine.
Topics: Cephalosporins; Chromatography, Liquid; Humans; Limit of Detection; Linear Models; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2020 |
Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Body Weight; Bronchoalveolar Lavage Fluid; Cephalosporins; Creatinine; Female; Humans; Male; Middle Aged; Plasma; Pneumonia, Ventilator-Associated; Tazobactam; Young Adult | 2021 |
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; DNA, Bacterial; Double-Blind Method; Drug Resistance, Bacterial; Healthcare-Associated Pneumonia; Humans; Meropenem; Multicenter Studies as Topic; Multilocus Sequence Typing; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Tazobactam; Treatment Outcome | 2021 |
Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferior
Topics: Adult; Anti-Bacterial Agents; Australia; beta-Lactamases; Cephalosporins; Clostridioides difficile; Escherichia coli; Humans; Italy; Lebanon; Meropenem; Microbial Sensitivity Tests; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Saudi Arabia; Sepsis; Singapore; Spain; Tazobactam | 2021 |
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Equivalence Trials as Topic; Female; Healthcare-Associated Pneumonia; Humans; Logistic Models; Male; Meropenem; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Tazobactam | 2021 |
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Probability; Renal Insufficiency; Tazobactam; Treatment Outcome | 2021 |
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Tazobactam; Ventilators, Mechanical | 2022 |
The effects of antibiotic cycling and mixing on acquisition of antibiotic resistant bacteria in the ICU: A post-hoc individual patient analysis of a prospective cluster-randomized crossover study.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross-Over Studies; Gram-Negative Bacteria; Humans; Intensive Care Units; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Tazobactam | 2022 |
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Bacterial; Retrospective Studies; Tazobactam; Ventilators, Mechanical | 2022 |
A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; China; Double-Blind Method; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Tazobactam | 2022 |
Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Kidney Failure, Chronic; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Probability; Renal Dialysis; Tazobactam; Ventilators, Mechanical | 2023 |
Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Topics: Anti-Bacterial Agents; Bacteria; Cephalosporins; Hospitals; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Tazobactam; Ventilators, Mechanical | 2023 |
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Hospitals; Humans; Meropenem; Monobactams; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Tazobactam; Vasoconstrictor Agents; Ventilators, Mechanical | 2022 |
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Infant, Newborn; Meropenem; Penicillanic Acid; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2023 |
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Child; Escherichia coli; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Penicillanic Acid; Tazobactam | 2023 |
337 other study(ies) available for tazobactam and cephalosporin c
| Article | Year |
|---|---|
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
Topics: Amino Acid Sequence; Bacillus; Bacterial Proteins; beta-Lactamases; Chromosome Mapping; Chromosomes, Bacterial; Cloning, Molecular; Microbial Sensitivity Tests; Molecular Sequence Data; Molecular Weight; Sequence Homology, Amino Acid; Substrate Specificity | 2007 |
Characterization of a beta-lactamase produced by Pseudomonas paucimobilis.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Chromosomes, Bacterial; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Molecular Weight; Penicillanic Acid; Penicillin Resistance; Penicillins; Pseudomonas; Sulbactam; Tazobactam | 1991 |
In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefotaxime; Cefozopran; Cefpirome; Cephalosporins; Drug Stability; Enterobacteriaceae; Hydrolysis; Microbial Sensitivity Tests; Moxalactam; Penicillanic Acid; Piperacillin; Tazobactam | 1991 |
In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Microbial; Drug Synergism; Enterobacteriaceae; Gram-Negative Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Staphylococcus; Tazobactam | 1990 |
Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acids; DNA, Bacterial; Drug Resistance, Microbial; Drug Synergism; Enterobacteriaceae; Genes, Bacterial; Humans; Nucleic Acid Hybridization; Penicillanic Acid; Penicillin Resistance; Penicillins; R Factors; Sulbactam; Tazobactam | 1988 |
[In vitro activity of six beta-lactams against 295 strains of enterobacteriaceae and P. aeruginosa isolated from neutropenic patients].
Topics: Cefepime; Cefotaxime; Cefpirome; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 1995 |
beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cell Division; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Isoniazid; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium avium; Penicillanic Acid; Streptomycin; Sulbactam; Tazobactam | 1995 |
Interaction of tazobactam with Staphylococcus aureus PC1 beta-lactamase: a molecular modelling and enzyme kinetics study.
Topics: Amino Acid Sequence; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Cephalosporins; Computer Simulation; Models, Molecular; Molecular Sequence Data; Penicillanic Acid; Peptide Fragments; Staphylococcus aureus; Tazobactam | 1994 |
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Hydrolysis; Isoelectric Focusing; Kinetics; Molecular Weight; Penicillanic Acid; Spectrophotometry, Ultraviolet; Tazobactam | 1993 |
Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefotaxime; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Drug Combinations; Drug Therapy, Combination; Female; Klebsiella Infections; Klebsiella pneumoniae; Lung; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia, Bacterial; Tazobactam; Ticarcillin | 1996 |
Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Campylobacter coli; Campylobacter jejuni; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Sulbactam; Tazobactam | 1996 |
Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Intensive Care Units; Klebsiella; Klebsiella Infections; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Piperacillin; Tazobactam | 1996 |
Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Ceftazidime; Cephalosporins; Ciprofloxacin; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Therapy, Combination; Enterobacter cloacae; Enzyme Inhibitors; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serratia marcescens; Tazobactam; Ticarcillin; Time Factors | 1996 |
Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.
Topics: Abdominal Abscess; Animals; beta-Lactamases; Cefepime; Cephalosporins; Drug Therapy, Combination; Enzyme Inhibitors; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Rats; Rats, Sprague-Dawley; Tazobactam | 1997 |
Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Topics: Ampicillin; beta-Lactamase Inhibitors; Cefoperazone; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Retrospective Studies; Sulbactam; Tazobactam; Ticarcillin; Urinary Tract; Urinary Tract Infections | 1997 |
Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
Topics: Amoxicillin; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Ciprofloxacin; Clavulanic Acid; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Intensive Care Units; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Tazobactam | 1997 |
Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.
Topics: Amoxicillin; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Enzyme Inhibitors; Escherichia coli; Models, Molecular; Mutagenesis, Site-Directed; Penicillanic Acid; Penicillins; Phenotype; Tazobactam | 1998 |
Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporins; Clavulanic Acid; Drug Interactions; Drug Resistance, Multiple; Enzyme Inhibitors; Isoelectric Focusing; Microbial Sensitivity Tests; Molecular Sequence Data; Monobactams; Penicillanic Acid; Providencia; Sulbactam; Tazobactam | 1998 |
Efficacy of beta-lactam and inhibitor combinations in a diffusion chamber model in rabbits.
Topics: Animals; Ceftriaxone; Cephalosporin Resistance; Cephalosporins; Colony Count, Microbial; Diffusion Chambers, Culture; Drug Therapy, Combination; Enterobacter; Enterobacteriaceae; Enterobacteriaceae Infections; Enzyme Inhibitors; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Rabbits; Tazobactam | 1999 |
In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor.
Topics: Animals; beta-Lactamase Inhibitors; beta-Lactamases; Cefpirome; Ceftazidime; Cephalosporins; Citrobacter freundii; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae; Enzyme Induction; Enzyme Inhibitors; Female; Male; Mice; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 1999 |
In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Topics: Acinetobacter; Anti-Bacterial Agents; Austria; beta-Lactam Resistance; Carbapenems; Cephalosporins; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonadaceae; Tazobactam; Thienamycins | 1999 |
Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
Topics: Anti-Bacterial Agents; Bacteria; Cefepime; Ceftazidime; Cephalosporins; Creatinine; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Piperacillin; Tazobactam; Time Factors | 1999 |
High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae.
Topics: Bacterial Outer Membrane Proteins; Base Sequence; beta-Lactamases; Biological Transport; Ceftazidime; Cephalosporins; Chromosomes; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Microbial; Enzyme Inhibitors; Gene Expression Regulation, Bacterial; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleic Acid Hybridization; Penicillanic Acid; Penicillins; Piperacillin; Promoter Regions, Genetic; Sequence Homology, Nucleic Acid; Tazobactam | 2000 |
Control of glycopeptide-resistant enterococci in an oncology unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cohort Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Fever; Glycopeptides; Humans; Infection Control; Neoplasms; Neutropenia; Oncology Service, Hospital; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2000 |
Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit.
Topics: Burn Units; Cephalosporins; Clinical Protocols; Cross Infection; Drug Utilization; Enterococcus; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Methicillin Resistance; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Staphylococcal Infections; Staphylococcus aureus; Tazobactam; Vancomycin; Vancomycin Resistance; Wounds and Injuries | 2000 |
Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acid; Drug Resistance, Microbial; Drug Resistance, Multiple; Enzyme Inhibitors; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Proteus Infections; Proteus mirabilis; Tazobactam | 2001 |
Thermophilic multidrug-resistant Campylobacter fetus infection with hypersplenism and histiocytic phagocytosis in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Campylobacter fetus; Campylobacter Infections; Ceftazidime; Cephalosporins; Diarrhea; Drug Resistance, Microbial; Enzyme Inhibitors; Erythromycin; Histiocytes; Histiocytosis; Humans; Hypersplenism; Male; Penicillanic Acid; Penicillins; Phagocytosis; Piperacillin; Quinolones; Splenic Infarction; Splenomegaly; Tazobactam | 2001 |
Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Chromosomes, Bacterial; Drug Resistance, Microbial; Enterobacteriaceae; Enzyme Inhibitors; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2001 |
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins | 2002 |
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
Topics: Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sensitivity and Specificity; Tazobactam | 2002 |
[Pharmacokinetics of antibiotics in inflamed and healthy lung tissue].
Topics: Anti-Bacterial Agents; Cefpirome; Cephalosporins; Empyema, Pleural; Extracellular Space; Humans; Lung; Microbial Sensitivity Tests; Microdialysis; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Tazobactam; Thoracotomy | 2003 |
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Colony Count, Microbial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Enzyme Inhibitors; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Moxifloxacin; Penicillanic Acid; Penicillins; Piperacillin; Quinolines; Tazobactam | 2004 |
In vitro antimicrobial activity of doripenem, a new carbapenem.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Cephalosporins; Doripenem; Drug Therapy, Combination; Enterobacteriaceae; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Tazobactam | 2004 |
Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixe
Topics: Abscess; Animals; Bacteroides fragilis; Ceftizoxime; Cephalosporins; Colony Count, Microbial; Drug Resistance; Enterobacter cloacae; Enzyme Inhibitors; Female; Mice; Mice, Inbred BALB C; Mutation; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2004 |
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Escherichia coli; Escherichia coli Infections; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2004 |
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Culture Media, Conditioned; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam; Thienamycins | 2004 |
In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor.
Topics: Azepines; Bacteria; beta-Lactamases; Ceftazidime; Cephalosporins; Clavulanic Acid; Dealkylation; Enzyme Inhibitors; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Staphylococcus aureus; Sulfuric Acid Esters; Tazobactam | 2004 |
In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ceftriaxone; Cephalosporins; Drug Therapy, Combination; Enterobacteriaceae; Enzyme Inhibitors; Hospital Units; In Vitro Techniques; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2005 |
Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Brain; Cefepime; Cefixime; Cephalosporins; Confusion; Consciousness Disorders; Delirium; Epididymitis; Humans; Kidney; Male; Metabolic Clearance Rate; Neurotoxicity Syndromes; Penicillanic Acid; Piperacillin; Recovery of Function; Secondary Prevention; Systemic Inflammatory Response Syndrome; Tazobactam; Urinary Tract Infections; Withholding Treatment | 2005 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospita
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporin Resistance; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Enterobacteriaceae Infections; Enzyme Inhibitors; Escherichia coli; Greece; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Prospective Studies; Tazobactam; Time Factors | 2007 |
Control of multi-resistant bacteria and ventilator-associated pneumonia: is it possible with changes in antibiotics?
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Hospitals, University; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Tazobactam | 2007 |
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
Topics: Aztreonam; beta-Lactamases; Carbapenems; Catalysis; Cephalosporins; Clavulanic Acid; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Hydrolysis; Kinetics; Molecular Weight; Penicillanic Acid; Penicillins; Recombinant Proteins; Serratia; Sulbactam; Tazobactam | 2007 |
Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Humans; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Urinary Tract Infections | 2008 |
Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime.
Topics: Anti-Bacterial Agents; Bacteria; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Gram-Positive Bacteria; Penicillanic Acid; Tazobactam | 2008 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Young Adult | 2010 |
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Sepsis; Shock, Septic; Tazobactam; Thienamycins | 2010 |
Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Enzyme Inhibitors; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2010 |
Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.
Topics: Bacteroides fragilis; Cephalosporins; Drug Resistance, Bacterial; Enterobacteriaceae; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2011 |
In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Cephalosporins; Escherichia coli; Escherichia coli Infections; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Typing; Penicillanic Acid; Tazobactam | 2011 |
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2012 |
Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
Topics: Acetamides; Anti-Bacterial Agents; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Oxazolidinones; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Retrospective Studies; Tazobactam; Treatment Outcome; Vancomycin; Wounds and Injuries | 2013 |
AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Humans; India; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2012 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Female; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2013 |
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
Topics: Anti-Bacterial Agents; Area Under Curve; beta-Lactamases; Cephalosporins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Models, Biological; Molecular Sequence Data; Penicillanic Acid; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Tazobactam | 2013 |
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
Topics: Anti-Bacterial Agents; Canada; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2013 |
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Computer Simulation; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Escherichia coli; Escherichia coli Infections; Gene Expression; Half-Life; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Plasmids; Tazobactam | 2013 |
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).
Topics: Anti-Infective Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Hospitals; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; United States | 2013 |
Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement.
Topics: Aged; Anti-Bacterial Agents; Bacteriuria; Cefepime; Cephalosporins; Colon, Sigmoid; Cystectomy; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Postoperative Complications; Prevalence; Pyuria; Staphylococcus aureus; Sulfamethoxazole; Tazobactam; Thienamycins; Trimethoprim; Urinary Diversion; Urinary Tract Infections | 2014 |
Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteroides fragilis; Cephalosporins; Clostridium; Drug Combinations; Fusobacterium; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Prevotella; Propionibacterium; Tazobactam | 2014 |
Reliability-targeted HPLC-UV method validation--a protocol enrichment perspective.
Topics: Bayes Theorem; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Reproducibility of Results; Ritonavir; Spectrophotometry, Ultraviolet; Tazobactam | 2014 |
Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2014 |
Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.
Topics: Adolescent; Adult; Aged; Cephalosporins; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Penicillanic Acid; Prospective Studies; Tazobactam; Young Adult | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Antimicrobial activity of cefepime-tazobactam combination tested against clinical isolates of Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Humans; India; Penicillanic Acid; Tazobactam | 2014 |
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Citrobacter; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacter; Escherichia coli; Europe; Gram-Negative Aerobic Bacteria; Humans; Intraabdominal Infections; Klebsiella oxytoca; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Proteus mirabilis; Pseudomonas aeruginosa; Serratia; Tazobactam; United States; Urinary Tract Infections | 2014 |
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pneumonia, Bacterial; Tazobactam; United States | 2014 |
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cephalosporins; Cross Infection; Enterobacteriaceae; Enterobacteriaceae Infections; Europe; Genotype; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.
Topics: Anti-Bacterial Agents; Cephalosporins; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2014 |
In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.
Topics: Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; United States | 2014 |
Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.
Topics: Analytic Sample Preparation Methods; Anti-Bacterial Agents; Automation; Blood Chemical Analysis; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Ciprofloxacin; Humans; Isotopes; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Thienamycins; Time Factors | 2015 |
Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
Topics: Animals; beta-Lactamase Inhibitors; Cephalosporins; Clinical Trials as Topic; Enterobacteriaceae; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Investigational New Drug Application; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2015 |
Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Female; Klebsiella pneumoniae; Mice; Penicillanic Acid; Protein Binding; Tazobactam; Thigh | 2015 |
In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2015 |
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2015 |
A green capillary zone electrophoresis method for the simultaneous determination of piperacillin, tazobactam and cefepime in pharmaceutical formulations and human plasma.
Topics: Cefepime; Cephalosporins; Dosage Forms; Electrophoresis, Capillary; Green Chemistry Technology; Humans; Linear Models; Penicillanic Acid; Piperacillin; Reproducibility of Results; Sensitivity and Specificity; Tazobactam | 2015 |
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Topics: Adult; Anti-Infective Agents; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; United States | 2015 |
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
Topics: Adaptation, Physiological; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Gene Expression; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protein Structure, Secondary; Protein Structure, Tertiary; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2015 |
Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.
Topics: Anti-Bacterial Agents; Cephalosporins; Clostridioides difficile; Microbial Sensitivity Tests; Penicillanic Acid; Phylogeny; Tazobactam | 2015 |
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2015 |
Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Bioreactors; Cephalosporins; Chromatography, High Pressure Liquid; Colony Count, Microbial; Computer Simulation; Escherichia coli; Gene Expression; Half-Life; Infusion Pumps; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Porins; Pseudomonas aeruginosa; Tazobactam | 2016 |
Evaluation of CTX-M steady-state mRNA, mRNA half-life and protein production in various STs of Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Disk Diffusion Antimicrobial Tests; Escherichia coli; Genotype; Humans; Immunoblotting; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA Stability; RNA, Messenger; Tazobactam | 2016 |
Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.
Topics: Anti-Bacterial Agents; Cephalosporins; Child; Humans; Intraabdominal Infections; Penicillanic Acid; Tazobactam | 2016 |
Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Topics: Anti-Bacterial Agents; Cephalosporins; Critical Illness; Drug Resistance, Multiple, Bacterial; Hemofiltration; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Prospective Studies; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2015 |
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cephalosporins; Computer Simulation; Dose-Response Relationship, Drug; Escherichia coli; Gene Expression; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Tazobactam | 2016 |
Characterization of VCC-1, a Novel Ambler Class A Carbapenemase from Vibrio cholerae Isolated from Imported Retail Shrimp Sold in Canada.
Topics: Amino Acid Sequence; Animals; Aztreonam; Bacterial Proteins; Base Sequence; beta-Lactamases; Canada; Carbapenems; Cephalosporins; Clavulanic Acid; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Penaeidae; Penicillanic Acid; Penicillins; Seafood; Sequence Alignment; Sequence Analysis, DNA; Tazobactam; Vibrio cholerae | 2016 |
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 2016 |
Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Plasma; Reproducibility of Results; Sodium Chloride; Swine; Tazobactam | 2016 |
Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
Topics: Anti-Bacterial Agents; Cefazolin; Cephalosporins; Daptomycin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillanic Acid; Staphylococcus aureus; Tazobactam | 2016 |
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.
Topics: Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Biofilms; Cephalosporins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Child; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Leukemia; Male; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Female; Humans; Liver Abscess; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam | 2018 |
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
Topics: Aged; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; Cephalosporins; Chromatography, High Pressure Liquid; Critical Illness; Drug Resistance, Multiple, Bacterial; Hemofiltration; Humans; Male; Penicillanic Acid; Plasma; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome; United States | 2016 |
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2016 |
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2016 |
Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Off-Label Use; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Cephalosporin Resistance; Cephalosporins; Clavulanic Acid; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Germany; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Tazobactam; Young Adult | 2017 |
Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Salvage Therapy; Shock, Septic; Survival Analysis; Tazobactam | 2017 |
Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Ceftazidime; Cephalosporins; Drug Combinations; Education, Medical, Continuing; Humans; Intensive Care Units; Penicillanic Acid; Tazobactam; United States | 2016 |
Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam | 2017 |
Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
Topics: Anti-Bacterial Agents; Cephalosporins; Chemistry, Pharmaceutical; Drug Incompatibility; Excipients; Glucose; Humans; Infusions, Intravenous; Injections, Intravenous; Nephelometry and Turbidimetry; Penicillanic Acid; Sodium Chloride; Solubility; Tazobactam; Urinary Tract Infections | 2017 |
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Cephalosporins; DNA, Bacterial; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Real-Time Polymerase Chain Reaction; Tazobactam | 2017 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tazobactam; Thienamycins | 2017 |
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Europe; Humans; Intraabdominal Infections; Israel; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Turkey; Urinary Tract Infections | 2017 |
Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.
Topics: Animals; Anti-Bacterial Agents; Cattle; Cephalosporins; Drug Dosage Calculations; Hemodialysis Solutions; Humans; Membranes, Artificial; Metabolic Clearance Rate; Models, Biological; Penicillanic Acid; Renal Replacement Therapy; Tazobactam | 2017 |
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Female; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2017 |
Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.
Topics: Acute-Phase Proteins; Aged; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Bacterial; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Successful treatment of multidrug-resistant
Topics: Cephalosporins; Cystectomy; Debridement; Drug Resistance, Multiple, Bacterial; Fistula; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas Infections; Pubic Symphysis; Tazobactam; Treatment Outcome | 2017 |
Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Child, Preschool; Drug Resistance, Multiple, Bacterial; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Salvage Therapy; Tazobactam; Treatment Outcome; Young Adult | 2017 |
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; United States | 2017 |
Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
Topics: Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2017 |
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.
Topics: Anti-Infective Agents; beta-Lactamase Inhibitors; Cephalosporins; Epidemiological Monitoring; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Polymerase Chain Reaction; Tazobactam; United Kingdom | 2017 |
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; Cephalosporins; Clinical Protocols; Drug Combinations; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Male; Metronidazole; Models, Econometric; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Tazobactam; United Kingdom | 2017 |
Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fractures, Bone; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2017 |
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporins; DNA Gyrase; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Porins; Pseudomonas aeruginosa; Tazobactam | 2017 |
Monotherapy of ceftazidime-avibactam and ceftolozane-tazobactam: two effective antimicrobial agents against multidrug-resistant organisms except for NDM-1 isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Penicillanic Acid; Tazobactam | 2017 |
Monotherapy of ceftazidime-avibactam and ceftolozane-tazobactam against multidrug-resistant organisms.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Penicillanic Acid; Tazobactam | 2017 |
In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents.
Topics: Amikacin; Aztreonam; Cephalosporins; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Tazobactam; Tigecycline | 2017 |
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Catheter-Related Infections; Ceftazidime; Cephalosporins; Cross Infection; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Disk Diffusion Antimicrobial Tests; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Guidelines as Topic; Humans; Penicillanic Acid; Quality Control; Tazobactam | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Multilocus Sequence Typing; Penicillanic Acid; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Wound Infection | 2017 |
Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cephalosporins; Cytoskeletal Proteins; Drug Resistance, Multiple, Bacterial; Germany; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Humans; Male; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Genome, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pennsylvania; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Young Adult | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2018 |
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Heart Transplantation; Heart-Assist Devices; Humans; Male; Middle Aged; Penicillanic Acid; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.
Topics: Bacteremia; Cephalosporins; Drug Resistance, Bacterial; Humans; Immunocompromised Host; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2017 |
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2018 |
Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenem-Resistant Enterobacteriaceae; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2018 |
Clinical efficacy and safety of cefepime-tazobactam in hospitalized patients in South India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Escherichia coli Infections; Female; Hospitalization; Humans; India; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Young Adult | 2018 |
Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; beta-Lactam Resistance; Cephalosporins; Humans; Indicator Dilution Techniques; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2018 |
Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
Topics: Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Cephalosporins; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Humans; Italy; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Whole Genome Sequencing | 2018 |
In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.
Topics: Canada; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gene Expression; Hospitalization; Humans; Isoenzymes; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Plasmids; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tazobactam; United States | 2018 |
Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Tazobactam; Urinary Tract Infections | 2018 |
Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Female; Fluoroquinolones; Gentamicins; Germany; Humans; Male; Middle Aged; Odds Ratio; Penicillanic Acid; Piperacillin; Risk Factors; ROC Curve; Tazobactam; Urinary Tract Infections | 2018 |
[Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016].
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Czech Republic; Drug Resistance, Bacterial; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Urinary Tract Infections | 2017 |
Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Oregon; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2018 |
Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cephalosporins; Humans; Infusions, Parenteral; Lung Abscess; Male; Microbial Sensitivity Tests; Middle Aged; Outpatients; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
Topics: Anti-Bacterial Agents; Burkholderia pseudomallei; Cephalosporins; Microbial Sensitivity Tests; Tazobactam | 2018 |
In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
Topics: Achromobacter denitrificans; Adult; beta-Lactamase Inhibitors; Burkholderia cenocepacia; Cephalosporins; Colistin; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Sputum; Stenotrophomonas maltophilia; Tazobactam | 2018 |
Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; Urinary Tract Infections | 2018 |
Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Female; Follow-Up Studies; Humans; Infection Control; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Escherichia coli; Escherichia coli Infections; Female; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity, Morbid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2018 |
Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; beta-Lactamases; Ceftazidime; Cephalosporins; Clone Cells; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Gene Expression; Humans; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Survival Analysis; Tazobactam | 2018 |
Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma.
Topics: Anti-Bacterial Agents; Cephalosporins; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Plasma; Tazobactam | 2018 |
Ceftolozane-tazobactam for the treatment of multidrug-resistant
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Dialysis; Tazobactam; Treatment Outcome | 2018 |
Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2018 |
NICE Guidance - Complicated urinary tract infections: ceftolozane/tazobactam: © NICE (2016) Complicated urinary tract infections: ceftolozane/tazobactam.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Costs; Drug Resistance, Multiple, Bacterial; Evidence-Based Medicine; Humans; Infusions, Intravenous; Patient Safety; Powders; Practice Guidelines as Topic; Risk Factors; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2018 |
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cross Infection; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam | 2018 |
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-
Topics: Anti-Infective Agents; Bacteremia; Cephalosporins; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Hospitals; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2018 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Burkholderia cepacia complex; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Humans; Microbial Sensitivity Tests; Sulfamethoxazole; Tazobactam; Trimethoprim | 2018 |
Activity of Ceftolozane-Tazobactam against
Topics: Anti-Bacterial Agents; Burkholderia pseudomallei; Cephalosporins; Cross Infection; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Humans; Melioidosis; Microbial Sensitivity Tests; Tazobactam | 2018 |
Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Prevalence; Tazobactam; United States; United States Department of Veterans Affairs; Veterans | 2018 |
Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2018 |
Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; Cephalosporins; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Theoretical; Tazobactam | 2018 |
Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
Topics: Aged; Cephalosporins; Drug Resistance, Multiple, Bacterial; Factor Analysis, Statistical; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2018 |
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Microbial Sensitivity Tests; Molecular Diagnostic Techniques; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Tazobactam | 2019 |
Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV.
Topics: Anti-Bacterial Agents; Cephalosporins; Chemical Fractionation; Chromatography, High Pressure Liquid; Extracellular Fluid; Healthy Volunteers; Humans; Infusions, Intravenous; Spectrophotometry, Ultraviolet; Tazobactam | 2019 |
In vitro susceptibility of Salmonella enterica serovar Typhi to ceftolozane/tazobactam.
Topics: Cephalosporins; Feces; Humans; Microbial Sensitivity Tests; Salmonella typhi; Tazobactam; Typhoid Fever | 2019 |
Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; Treatment Outcome | 2019 |
Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Cephalosporins; Female; Half-Life; Humans; Kidney Failure, Chronic; Middle Aged; Osteomyelitis; Pseudomonas aeruginosa; Renal Replacement Therapy; Tazobactam | 2018 |
Know your enemy: managing resistant Gram-negative infections.
Topics: Animals; Antimicrobial Stewardship; Azabicyclo Compounds; Carrier State; Ceftazidime; Cephalosporins; Drug Combinations; Drug Development; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Tazobactam | 2018 |
In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactams; Burkholderia cepacia complex; Burkholderia gladioli; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Tazobactam | 2019 |
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Taiwan; Tazobactam | 2019 |
Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Queensland; Tazobactam | 2018 |
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bone Diseases, Infectious; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2019 |
Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2019 |
Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Hospitals; Humans; Microbial Sensitivity Tests; Patients; Poland; Pseudomonas; Pseudomonas Infections; Tazobactam | 2019 |
Ceftolozane-Tazobactam Pharmacokinetics during Extracorporeal Membrane Oxygenation in a Lung Transplant Recipient.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Extracorporeal Membrane Oxygenation; Female; Humans; Lung Transplantation; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Transplant Recipients | 2019 |
Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Biofilms; Cephalosporins; Colistin; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Models, Theoretical; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Child; Child, Preschool; Europe; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Prospective Studies; Tazobactam; United States | 2019 |
Successful ceftolozane-tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa.
Topics: Cephalosporins; Child, Preschool; Endocarditis, Bacterial; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2019 |
Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Young Adult | 2019 |
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Scotland; Tazobactam; Whole Genome Sequencing | 2019 |
Letter to the Editor.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Pathology, Molecular; Pseudomonas aeruginosa; Tazobactam | 2019 |
Reply to Humphrey and Spafford.
Topics: Azabicyclo Compounds; Ceftazidime; Cephalosporins; Pathology, Molecular; Pseudomonas aeruginosa; Tazobactam | 2019 |
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Tazobactam; Urinary Tract Infections; Young Adult | 2019 |
Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Critical Illness; Dose-Response Relationship, Drug; Hemofiltration; Humans; Male; Tazobactam | 2019 |
Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Gram-Negative Bacteria; Humans; Middle Aged; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Taiwan; Tazobactam; Time Factors; Treatment Outcome; Urinary Tract Infections; Young Adult | 2019 |
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; United States | 2019 |
Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; International Cooperation; Logistic Models; Multicenter Studies as Topic; Neoplasms; Neutropenia; Observational Studies as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Research Design; Retrospective Studies; Tazobactam; Time Factors | 2019 |
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients
Topics: Azabicyclo Compounds; Burkholderia cepacia complex; Burkholderia gladioli; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Humans; Tazobactam | 2019 |
Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.
Topics: Abdomen; Adult; Aged; Ceftazidime; Cephalosporins; Female; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Respiratory System; Tazobactam; United States; Urinary Tract | 2020 |
Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Infusions, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2019 |
Local outbreak of extended-spectrum β-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cross Infection; Disease Outbreaks; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; France; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Whole Genome Sequencing | 2019 |
Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.
Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Cross Infection; Drug Resistance, Multiple, Bacterial; Genotype; Hospitals; Humans; Microbial Sensitivity Tests; O Antigens; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Serogroup; Serotyping; Spain; Tazobactam; Whole Genome Sequencing | 2019 |
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Qatar; Tazobactam; Whole Genome Sequencing | 2019 |
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2020 |
Can ceftolozane-tazobactam treat nosocomial pneumonia?
Topics: Cephalosporins; Cross Infection; Double-Blind Method; Humans; Meropenem; Pneumonia; Tazobactam | 2019 |
Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
Topics: Asia; Cephalosporins; Europe; Female; Global Health; Humans; Latin America; Male; Microbial Sensitivity Tests; North America; Pacific Islands; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Sepsis; Skin Diseases, Bacterial; Tazobactam | 2020 |
A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cephalosporins; Confidence Intervals; Continuous Renal Replacement Therapy; Critical Illness; Hemodiafiltration; Humans; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Tazobactam | 2019 |
Oxygenator Impact on Ceftolozane and Tazobactam in Extracorporeal Membrane Oxygenation Circuits.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Equipment Design; Extracorporeal Membrane Oxygenation; Humans; Infant; Infant, Newborn; Metabolic Clearance Rate; Oxygenators, Membrane; Tazobactam; Young Adult | 2020 |
Reply to "Hypokalaemia probably associated with ceftolozane/tazobactam treatment: Three case reports".
Topics: Cephalosporins; Humans; Hypokalemia; Tazobactam | 2020 |
Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Tazobactam; Urinary Tract Infections | 2020 |
Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights.
Topics: Cephalosporins; Continuous Renal Replacement Therapy; Critical Illness; Humans; Tazobactam | 2019 |
Effect of high-dose vitamin C therapy on severe burn patients: a nationwide cohort study.
Topics: Adult; Ascorbic Acid; Burns; Cephalosporins; Cohort Studies; Continuous Renal Replacement Therapy; Critical Illness; Humans; Tazobactam | 2019 |
[Evaluation of susceptibility of multidrug-resistant Pseudomonas aeruginosa strains against ceftolozane/tazobactam].
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Mass Spectrometry; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Real-Time Polymerase Chain Reaction; Reference Values; Reproducibility of Results; Tazobactam | 2019 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia - Authors' reply.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia.
Topics: Cephalosporins; Cross Infection; Doripenem; Double-Blind Method; Humans; Meropenem; Pneumonia, Ventilator-Associated; Tazobactam | 2020 |
Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Infections; Ceftazidime; Cephalosporins; Cost-Benefit Analysis; Drug Combinations; Hospitalization; Humans; Intraabdominal Infections; Italy; Meropenem; Models, Economic; Tazobactam | 2019 |
Reply to Vena et al.
Topics: Aminoglycosides; Cephalosporins; Humans; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Tazobactam | 2020 |
Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cross Infection; Healthcare-Associated Pneumonia; Humans; Pharmaceutical Preparations; Polymyxins; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome | 2020 |
Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances.
Topics: Cephalosporins; Continuous Renal Replacement Therapy; Tazobactam | 2020 |
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Tazobactam; United States | 2020 |
In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Intensive Care Units; Intraabdominal Infections; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Urinary Tract Infections | 2020 |
In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016).
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Escherichia coli; Escherichia coli Infections; Hospitalization; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Tazobactam | 2020 |
Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2020 |
Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children.
Topics: Adolescent; Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Neutropenia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome; Young Adult | 2020 |
[In-vitro Activity of Ceftolozane-Tazobactam in Combination with Various Antibiotics Against Multidrug-resistant Acinetobacter baumannii Isolated from Intensive Care Patients].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Tazobactam | 2020 |
High minimum inhibitory concentrations among derepressed AmpC-beta-lactamase-producing
Topics: Bacterial Proteins; beta-Lactamases; Brazil; Cephalosporins; Enterobacter cloacae; Humans; Microbial Sensitivity Tests; Tazobactam | 2020 |
Antimicrobial susceptibility of plastic-associated bacteria isolated from the ocean to novel antibiotics (delafloxacin, meropenem/vaborbactam, ceftolozane/tazobactam, ceftobiprole) - Can environmental bacteria be predictors of persistence of antibiotic ac
Topics: Antarctic Regions; Anti-Bacterial Agents; Bacteria; Boronic Acids; Cephalosporins; Drug Resistance, Microbial; Fluoroquinolones; Islands; Meropenem; Oceans and Seas; Plastics; Polystyrenes; Tazobactam | 2020 |
Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactamase Inhibitors; Cephalosporins; China; Drug Combinations; Drug Misuse; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Inappropriate Prescribing; India; Microbial Sensitivity Tests; Patient Care; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam; Tazobactam | 2020 |
Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Mutation; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Hungary; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Lung Transplantation; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United State
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2021 |
Gram-negative Bacteria With Difficult-to-Treat Resistance: A Moving Target.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Imipenem; Phenotype; Tazobactam | 2021 |
Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study.
Topics: Ambulatory Care; Anti-Bacterial Agents; Cephalosporins; Drug Stability; Elastomers; Humans; Infusion Pumps; Tazobactam; Temperature | 2020 |
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Greece; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Critical Illness; Extracorporeal Membrane Oxygenation; Humans; Swine; Tazobactam | 2020 |
Evaluation of ultra-rapid susceptibility testing of ceftolozane-tazobactam by a flow cytometry assay directly from positive blood cultures.
Topics: Anti-Bacterial Agents; Blood Culture; Cephalosporins; Flow Cytometry; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Portugal; Spain; Tazobactam | 2020 |
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Immunocompromised Host; Inpatients; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cephalosporins; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Imipenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Peritonitis; Tazobactam | 2020 |
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Europe; Europe, Eastern; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
Topics: Anti-Bacterial Agents; Cephalosporins; Healthcare-Associated Pneumonia; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Activity of ceftolozane/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Lebanon; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2020 |
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project.
Topics: Antimicrobial Stewardship; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Clinical Protocols; Drug Combinations; Humans; Interrupted Time Series Analysis; Medication Systems; Oxazolidinones; Practice Patterns, Physicians'; Spain; Tazobactam; Teicoplanin; Tetrazoles | 2020 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam; United States; Whole Genome Sequencing | 2021 |
Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Meningitis; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Tazobactam | 2021 |
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
Topics: Anti-Bacterial Agents; Cephalosporins; Continuous Renal Replacement Therapy; Critical Illness; Humans; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Renal Replacement Therapy; Tazobactam | 2021 |
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2021 |
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2021 |
Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Carbapenems; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tazobactam | 2020 |
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Spain; Tazobactam; Treatment Outcome | 2021 |
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Lactams; Male; Microbial Sensitivity Tests; Middle Aged; Pancytopenia; Pharmacovigilance; Retrospective Studies; Tazobactam | 2021 |
In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Serine; Tazobactam; Thigh | 2021 |
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018).
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Public Health Surveillance; Tazobactam; United States | 2021 |
A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies.
Topics: Anti-Bacterial Agents; Cephalosporins; Chromatography, Liquid; Humans; Pharmaceutical Preparations; Renal Replacement Therapy; Tandem Mass Spectrometry; Tazobactam | 2021 |
Real life experience with ceftolozane/tazobactam therapy for
Topics: Adult; Aged; Anti-Bacterial Agents; APACHE; Bacteremia; Cephalosporins; Comorbidity; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pseudomonas Infections; Tazobactam | 2021 |
Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam | 2021 |
In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cephalosporins; Clavulanic Acids; Drug Synergism; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2021 |
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Humans; Klebsiella pneumoniae; Respiratory Tract Infections; Tazobactam; United States | 2021 |
Ceftolozane/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Humans; Italy; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam; Young Adult | 2021 |
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2021 |
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Understanding the binding conformation of ceftolozane/tazobactam with Metallo-β-lactamases VIM-5 and IMP-7 of Pseudomonas aeruginosa: A molecular docking and virtual screening process.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Molecular Docking Simulation; Protein Conformation; Pseudomonas aeruginosa; Tazobactam | 2021 |
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Topics: Adult; Aged; Allografts; Anti-Bacterial Agents; Autografts; Azabicyclo Compounds; Bacteremia; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Retrospective Studies; Tazobactam; Treatment Outcome; Young Adult | 2021 |
What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections?
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2021 |
Ceftolozane/tazobactam and ceftazidime/avibactam antimicrobial activity against clinically relevant gram-negative bacilli isolated in Mexico.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cross-Sectional Studies; Drug Combinations; Enterobacteriaceae; Humans; Mexico; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Tazobactam | 2020 |
Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study.
Topics: Aged; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cohort Studies; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tazobactam | 2021 |
Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
Topics: Anti-Bacterial Agents; Canada; Cephalosporins; Humans; Leadership; Registries; Tazobactam | 2021 |
Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France.
Topics: Adult; Cephalosporins; Humans; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study.
Topics: Anti-Bacterial Agents; Cephalosporins; Healthy Volunteers; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Microdialysis; Penicillanic Acid; Prospective Studies; Pseudomonas aeruginosa; Tazobactam | 2021 |
[Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
Topics: Aftercare; Aged; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Patient Discharge; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2021 |
Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
In vitro characterization of Pseudomonas aeruginosa recovered in Portugal from low respiratory tract infections in ICU patients (STEP Study).
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam | 2021 |
Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Methods for the Quantification of Cefquinome, Ceftiofur, and Desfuroylceftiofuracetamide in Porcine Feces with Emphasis on Analyte Stability.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Calibration; Cephalosporins; Chromatography, High Pressure Liquid; Feces; Female; Furans; Injections, Intramuscular; Male; Observer Variation; Reproducibility of Results; Swine; Tandem Mass Spectrometry; Tazobactam | 2021 |
Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Taiwan; Tazobactam | 2022 |
Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis.
Topics: Anti-Bacterial Agents; Cephalosporins; Endocarditis; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2021 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Imipenem; Jupiter; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam | 2021 |
The role of tazobactam-based combinations for the management of infections due to extended-spectrum β-lactamase-producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Combinations; Enterobacteriaceae Infections; Humans; Pharmacists; Piperacillin, Tazobactam Drug Combination; Societies, Medical; Tazobactam; United States | 2021 |
Recommendations for antibiotic selection for severe nosocomial infections.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cross Infection; Humans; Tazobactam | 2021 |
Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2022 |
Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.
Topics: Anti-Bacterial Agents; Cephalosporins; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Meropenem; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Thailand | 2022 |
In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Tazobactam | 2022 |
In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam.
Topics: Azabicyclo Compounds; Burkholderia pseudomallei; Ceftazidime; Cephalosporins; Humans; Melioidosis; Pseudomonas aeruginosa; Tazobactam; Thailand | 2022 |
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT.
Topics: Cephalosporins; Humans; Meropenem; Tazobactam | 2022 |
Pharmacokinetic/Pharmacodynamic Simulations of Cost-Effective Dosage Regimens of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Patients with Renal Impairment.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cost-Benefit Analysis; Drug Combinations; Humans; Microbial Sensitivity Tests; Tazobactam | 2022 |
Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2022 |
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Clone Cells; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Saudi Arabia; Tazobactam | 2022 |
Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Tertiary Care Centers | 2022 |
Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Drug resistance rates of difficult to treat Pseudomonas aeruginosa isolates to ceftolozane-tazobactam and ceftazidime-avibactam from a tertiary hospital, Singapore.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Singapore; Tazobactam; Tertiary Care Centers | 2022 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States | 2022 |
In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Combinations; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Rifampin; Tazobactam; Tigecycline | 2022 |
Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Monitoring; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Cyclooctanes; Enterobacteriaceae; Gram-Negative Bacteria; Hydrazines; Lactams; Microbial Sensitivity Tests; Piperidines; Pseudomonas aeruginosa; Tazobactam | 2022 |
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Cyclooctanes; Humans; Imipenem; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
The plethora of resistance mechanisms in Pseudomonas aeruginosa: transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel β-lactam/β-lactamase inhibitor combinations.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Gene Expression Profiling; Humans; Lactams; Lipopolysaccharides; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Meropenem; Microbial Sensitivity Tests; New Zealand; Penicillanic Acid; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2022 |
Molecular and Kinetic Characterization of MOX-9, a Plasmid-Mediated Enzyme Representative of a Novel Sublineage of MOX-Type Class C β-Lactamases.
Topics: Bacterial Proteins; beta-Lactamases; Cephalosporins; Clavulanic Acid; Kinetics; Plasmids; Sulbactam; Tazobactam | 2022 |
Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family β-Lactamase from Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aspartic Acid; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporinase; Cephalosporins; Glycine; Humans; Microbial Sensitivity Tests; Phenylalanine; Pseudomonas aeruginosa; Pseudomonas Infections; Serine; Tazobactam | 2022 |
Computational and data mining studies to understand the distribution and dynamics of Temoneria (TEM) β-lactamase and their interaction with β-lactam and β-lactamase inhibitors.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Data Mining; Molecular Docking Simulation; Monobactams; Penicillins; Tazobactam | 2022 |
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Topics: Ampicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Klebsiella pneumoniae; Levofloxacin; Meropenem; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Tazobactam; Tigecycline | 2022 |
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Monobactams; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Cefepime pharmacodynamic targets against Enterobacterales employing neutropenic murine lung infection and in vitro pharmacokinetic models.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Lung; Mice; Microbial Sensitivity Tests; Tazobactam | 2022 |
Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2022 |
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020.
Topics: Anti-Bacterial Agents; Cephalosporins; Czech Republic; Humans; Hungary; Imipenem; Microbial Sensitivity Tests; Poland; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
Topics: Adolescent; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Child; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil.
Topics: Anti-Bacterial Agents; beta-Lactamases; Brazil; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Hospitals, General; Klebsiella pneumoniae; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2023 |
Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Enterobacteriaceae; Escherichia coli; Humans; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Biochemical Insights into Imipenem Collateral Susceptibility Driven by
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporinase; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Klebsiella pneumoniae; Pseudomonas aeruginosa; Tazobactam | 2023 |
Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Intraabdominal Infections; Metronidazole; Penicillanic Acid; Tazobactam | 2023 |
Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporinase; Cephalosporins; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Topics: Adolescent; Anti-Bacterial Agents; Biofilms; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |
Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia.
Topics: Adult; Anti-Bacterial Agents; Australia; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Cohort Studies; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam | 2023 |
Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
Topics: Anti-Bacterial Agents; Cephalosporins; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin | 2023 |